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Ischemic heart disease is the leading cause of death in the western society and is becoming 
increasingly a major health problem in developing countries. In the current study, the role of 
hydrogen sulfide (H2S) in the cardioprotection against ischemic injury was investigated in both 
in vitro and in vivo models.  
The effects of endogenous and exogenous H2S were first examined in isolated adult rat 
cardiomyocytes. Endogenous H2S production was found to be suppressed in cardiomyocytes 
subjected to lethal ischemia. Preconditioning the cells with brief ischemia partly restored 
endogenous H2S level. Inhibition of H2S biosynthesis blocked the early and late cardioprotection 
induced by ischemic preconditioning, indicating that endogenous H2S was necessary for the 
development of both early and late cardioprotection of ischemic preconditioning. To examine the 
effect of exogenous H2S, cardiomyocytes were preconditioned with a H2S donor, NaHS, at 
concentrations of 10-6 to 10-3 mol/L. H2S preconditioning produced a concentration-dependent 
protection against ischemia-caused cell death, morphology change and impairment on cell 
function. A time course study showed that H2S-induced cardioprotection occurred in 2 time 
windows (early phase, ~1 h, and late phase, 16-28 h) and was effective to counteract different 
periods of ischemia and reperfusion. The late cardioprotection was blocked in the presence of a 
sarcolemmal KATP channel blocker, a nitric oxide synthase inhibitor or a PKC inhibitor, 
suggesting their involvement in the signaling pathway of H2S preconditioning. Western blotting 
analysis confirmed that H2S preconditioning activated three isoforms of PKC, α, ε and δ. The 
activated PKC mediated the acceleration of cytosolic Ca2+ clearing which in turn prevented 
cytosolic Ca2+ accumulation and myocytes hypercontracture during ischemia and reperfusion.   
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In a rat model of myocardial infarction, the effect of H2S was examined in vivo with 
intraperitoneal injection of NaHS. Assessment of infarct size revealed that a single bolus of 
NaHS administered one day before MI reduced infarct size by 78% at the optimal dose of 
1µmol/kg, whereas rats receiving three boluses of NaHS once per day after MI only displayed a 
maximum reduction of 38% in infarct size. A combined treatment of both preconditioning and 
post-treatment did not produce stronger protection than that produced by H2S preconditioning 
alone. Furthermore, H2S preconditioning also remarkably reduced LV dilatation and wall 
thinning, as manifested by LV internal diameter and anterior wall thickness.  
In conclusion, the current study has demonstrated that H2S is a potent cardioprotective agent 
against ischemic injury. H2S preconditioning may represent an effective and promising 













Chapter 1 Introduction 
1.1 General Overview  
Ischemic heart disease, mainly manifested by myocardial infarction, is a syndrome 
characterized by high mortality, frequent hospitalization and reduced life quality. As a 
global health problem, ischemic heart disease is cited as the leading cause of death in 13 
countries, primarily in US and most European countries (American Heart Association, 
2008). In Singapore, ischemic heart disease accounts for 18.5% of total death, ranked as 
the second most common cause of mortality in 2006 (Ministry of Health, 2006).  
Despite remarkable advances in basic science and clinical studies, preventing and 
reversing ischemic heart disease remains a great challenge to scientists and clinicians 
working for the health of millions of patients worldwide. In the 20th century, classical 
physiology studies provided valuable insight into the pathophysiology of myocardial 
ischemia and reperfusion. Next to reperfusion therapy, preconditioning of the heart with 
nonlethal ischemic episodes emerged in the late 1980s as a promising means to limit 
damage by myocardial infarction. It then became clear that the cardioprotective effect of 
preconditioning is mediated by certain signal transduction molecules. Elucidating the 
intracellular signal transduction mediated by these molecules allowed the identification of 
pharmacological agents that can mimic the cardioprotection without ischemia. Studies 
driven by this particular interest have derived a special field in the cardioprotection called 
pharmacological preconditioning and translation of the basic science findings from this 
field into clinical use is yielding encouraging results.    
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Over the past decades, the focus of research in cardioprotection against myocardial 
ischemia has shifted from physiology and biochemical studies at whole organ level to 
molecular studies at organelle and intracellular level. The use of biochemistry, cellular 
and molecular biology, genomics, and proteomics has become more important to identify 
the signaling complexes mediating cardioprotection against I/R injury. It is expected that 
utilization of these technologies will bring a better understanding of the progression of 
the disease and enable the researchers to develop more effective interventions for 
ischemic heart disease.  
1.2 Ischemic heart disease  
1.2.1 Epidemiology  
Ischemic heart disease, also called coronary heart disease, is the leading cause of death in 
western society, claiming hundreds of thousands of lives each year. In the United States, 
for instance, some 8,700,000 men and 7,300,000 women are living with ischemic heart 
disease (American Heart Association, 2008). Every year, an estimated 920,000 people 
suffer a new or recurrent coronary attack, and about 38% of them die as a result of the 
attack (American Heart Association, 2008). In the developing countries, the death rate 
from ischemic heart disease is third to AIDS and lower respiratory infections (CGIRS, 
2006). The World health organization (WHO) predicts that ischemic heart disease will 
cause 11.1 million deaths globally in 2020, becoming the top killer of humans in the 
whole world (World Health Organization web site, www.who.int/ncd/cvd).  
1.2.2 Risk factors  
Atherosclerosis is a major cause of ischemic heart disease. The risk factors for 
atherosclerosis are generally those for ischemic heart disease. Extensive clinical and 
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statistical studies have identified several factors that significantly increase the risk of 
coronary heart disease (American Heart Association web site, 
http://www.americanheart.org/presenter.jhtml?identifier=4726). Some of the factors 
cannot be changed, including older age, male gender, race and heredity, while many 
others are modifiable, like tobacco smoke, high blood cholesterol, high blood pressure, 
physical inactivity, obesity and diabetes mellitus, all of which can be treated or controlled 
either by changing lifestyle or taking medicine.  
1.2.3 Pathology 
Myocardial infarction (MI) is a common presentation of ischemic heart disease. A 
myocardial infarction occurs when an atherosclerotic plaque that slowly builds up in the 
lumen of a coronary artery suddenly ruptures and blocks the blood flow downstream. The 
formation of atherosclerotic plaque is a chronic inflammatory response in the walls of 
arteries, in large part due to the accumulation of white blood cells and low density 
lipoproteins (LDL, the proteins carrying cholesterol and triglycerides). When LDL gets 
through an artery, oxygen free radicals react with it and form oxidized-LDL, which then 
attracts macrophages and T-lymphocytes. After these white blood cells take up large 
amounts of cholesterol, they are called foam cells. When foam cells die, their contents are 
released, which attracts more macrophages and creates an extracellular lipid core in the 
inner surface of atherosclerotic plaque. Conversely, the outer, older portions of the plaque 
become calcified and stiffer over time. After decades of progression, these plaques may 
rupture, activate the blood clotting system and lead to the formation of a thrombus, which 
obstructs blood flow acutely. Upon the obstruction, downstream myocardium is starved 
of oxygen and nutrients, where myocardial infarction develops. Most individuals with 
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coronary heart disease show no evidence of narrowed artery for decades until the disease 
progresses to the advanced state when the first symptom, often a "sudden" heart attack, 
finally arise (American Heart Association, 2008).  
The myocardium can tolerate brief periods (up to 15 minutes) of severe myocardial 
ischemia without resulting cardiomyocyte death (Buja, 1998). If impaired blood flow 
lasts more than 20-30 minutes, it will usually initiate irreversible cell injury (infarction). 
With increasing duration of ischemia, greater cardiomyocyte damage could develop upon 
a re-established blood flow to the blocked heart area, termed reperfusion injury (Yellon 
and Baxter, 2000). The intracellular events of ischemia and reperfusion injury will be 
discussed in detailed in the session 1.2.6 “Myocardial ischemia and reperfusion injury”.  
1.2.4 Clinical features and diagnosis   
The diagnosis of cardiac ischemia is usually made by integrating the symptoms and the 
results from physical examinations with biomarker, electrocardiography (ECG) or other 
imaging techniques (Antman et al., 2004). Chest pain is the most common symptom of 
acute myocardial infarction and is often described as a sensation of tightness, pressure, or 
squeezing. Chest pain due to ischemia of the heart muscle is termed angina pectoris.  
Cardiac biomarkers are proteins released into the bloodstream from the damaged 
myocytes, such as myoglobin, cardiac troponin T and I, creatine kinase (CK), lactate 
dehydrogenase (LDH) and so on. Myocardial necrosis can be recognized when blood 
levels of specific biomarkers are increased. Disproportional elevation of the MB subtype 
of the enzyme CK was found very specific for myocardial injury. Elevated troponins in 
the setting of chest pain may also indicate a high likelihood of a myocardial infarction 
(Aviles et al., 2002). 
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Electrocardiography plays an important role in the diagnosis of patients with 
suspected myocardial infarction (Thygesen et al., 2007). The acute or evolving changes 
in the ST-T waveforms and the Q-waves allow the clinician to date the event, suggest the 
infarct-related artery and estimate the amount of myocardium at risk. The earliest 
manifestations of myocardial ischemia are typical T waves and ST segment changes. As 
the myocardial infarction evolves, there may be loss of R wave height and development 
of pathological Q waves.  
Non-invasive imaging is also useful in diagnosis and characterization of myocardial 
infarction with the ability to detect wall abnormities (Thygesen et al., 2007). Commonly 
used imaging techniques in acute and chronic infarction are echocardiography, 
radionuclide ventriculography and magnetic resonance imaging (MRI). 
Echocardiography is an excellent real-time imaging technique with strength in the 
assessment of wall thickness, thickening and motion at rest. Radionuclide imaging allows 
viable myocytes to be visualized directly, presenting the only commonly available direct 
method of assessing viability. Cardiovascular MRI is well-validated standard for the 
assessment of myocardial function with high spatial resolution and moderate temporal 
resolution. It is, however, more cumbersome and less used in an acute setting.  
1.2.5 Complications 
Life-threatening complications may occur immediately following the heart attack. These 
include pulmonary congestion, ventricular rupture, arrhythmia, pericarditis and 
cardiogenic shock (Antman et al., 2004). A chronic remodeling progress may also start 
from the injured site and ultimately leads to heart failure.   
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1.2.6 Myocardial ischemia and reperfusion (I/R) injury 
1.2.6.1 Cellular injury 
Intensive investigation over decades has provided a detailed understanding of the 
complexity of the response of myocardium to an ischemic insult. Myocardial ischemia 
results in a characteristic pattern of metabolic and ultrastructural changes that lead to 
irreversible injury. Upon the interruption of oxygen supply, mitochondrial oxidative 
phosphorylation rapidly stops, resulting loss of the major source of ATP production for 
energy metabolism. A compensatory increase in anaerobic glycolysis for ATP production 
leads to the accumulation of hydrogen ions and lactate (Buja, 2005). The resultant 
intracellular acidosis causes alterations in ion transport in the sarcolemma and organellar 
membranes (Buja et al., 1988) (Thandroyen et al., 1992). Initially, there is increased K+ 
efflux related to an increased osmotic load due to the accumulation of metabolites and 
inorganic phosphate. With a substantial decline in ATP, the Na+, K+-ATPase is inhibited, 
resulting in a further decline of K+ and an increase in Na+. Intracellular acidosis also 
activates the sarcolemmal Na+–H+ antiport (Yellon and Baxter, 2000; Karmazyn, 1999), 
which facilitates proton extrusion in exchange for Na+. The accumulated Na+ in turn 
activates Na+–Ca2+ exchanger which extrudes Na+ and brings in Ca2+. The resultant 
cytosolic loading of Ca2+ not only induces sustained impairment on contractile function, 
but also mediates the damage on cell membrane, which leads to the progression of the 
injury to an advanced stage (Buja, 1991).  
The increase in cytosolic Ca2+ activates Ca2+–dependent protease and phospholipase 
which degrades phospholipid and releases lysophospholipids and free fatty acids. 
Peroxidative stress continuously mounts with accumulation of toxic oxygen species and 
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free radicals generated from myocytes, endothelial cells, and activated leukocytes, 
inducing further damage to the membrane phospholipid. Activated proteases cleave 
cytoskeletal filaments, which disrupts the cellular scaffolds. These changes collectively 
lead to a loss of membrane integrity and terminally demolish the cell structure.  
1.2.6.2 Necrosis and apoptosis of cardiac cells 
Necrosis and apoptosis represents the two fundamental forms of cell death:  cell injury 
with swelling, known as necrosis, and cell injury with shrinkage, known as apoptosis 
(Majno and Joris, 1995). Necrosis occurs when cells are exposed to extreme stumili like 
ischemia and ends with total cell lysis. Due to the plasma membrane breakdown, 
cytoplasmic contents including lysosomal enzymes are released into the extracellular 
environment. Therefore, necrotic cell death is often associated with massive tissue 
damage and an intense inflammatory response. Apoptosis, in contrast, can occur under 
physiological or pathological conditions. Cells undergoing apoptosis feature partition of 
cytoplasm and nucleus into membrane bound-vesicles (apoptotic bodies) which contain 
ribosomes, morphologically intact mitochondria and nuclear material. Thus, no 
inflammatory response is elicited in vivo due to efficient removal of apoptotic bodies by 
macrophages or adjacent epithelial cells.  
Extensive investigation has pointed to necrosis as the chief form of cardiomyocyte 
death during ischemic injury. However, more recently, a role of apoptosis has been 
identified in many forms of cardiac pathology, including myocardial ischemia (Buja and 
Entman, 1998). The rate and magnitude of ATP depletion are determinants of whether 
cell injury progresses by apoptosis or necrosis because apoptosis is an ATP-dependent 
process (Buja, 2005). Generally, in the central region of the infarct, necrosis 
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predominates, while in the peripheral areas there is a mix of necrosis and apoptosis. 
Despite little acute cell death in the remote myocardium, increasing levels of both forms 
of cell death are noted during the late phases (Mani K, 2008). As the severity of ischemia 
declines and reperfusion supervenes, the quantum of necrosis decreases, while that of 
apoptosis increases (Anversa et al., 1998). 
1.2.6.3 Reperfusion injury 
Reintroduction of coronary flow to the infracted area is necessary to resuscitate the 
ischemic myocardium and limit the extent of myocardial necrosis. However, the effects 
of reperfusion are complex and may include some deleterious consequences collectively 
referred to as reperfusion injury (Yellon and Baxter, 2000). This reperfusion injury is 
manifested by myocardial stunning, microvascular dysfunction and expedition of cell 
death in certain critically injured myocytes. The major mediators of reperfusion injury are 
free oxygen radicals, overloaded calcium, and neutrophils (Carden and Granger, 2000; 
Granger, 1999; Park and Lucchesi, 1999). The oxygen radicals are generated by injured 
myocytes and endothelial cells, as well as neutrophils activated on reperfusion. Free 
radicals exacerbate membrane damage and stimulate vasoconstriction, which, when 
severe enough, cause a “no-flow” phenomenon. Impaired intracellular calcium 
homeostasis also plays an important role in the reperfusion injury. The overloaded 
calcium induces maximum contraction of the myofibrils upon reperfusion, resulting in a 
disruptive type of necrosis, termed contraction band necrosis (Verma et al., 2002). An 
increase in mitochondrial [Ca2+] triggers the opening of mitochondrial permeability 
transition pore (mPTP) and leads to the release of cytochrome C and other proapoptotic 
factors that initiates the apoptotic cascade (Halestrap et al., 2004). Reperfusion is also a 
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potent stimulus for neutrophil activation and accumulation, which in turn serve as potent 
stimuli for reactive oxygen species production. The neutrophils accumulate in the 
microcirculation, release inflammatory mediators, and contribute to microvascular 
obstruction and the no-reflow phenomenon.  
1.3 Interventions for cardiac ischemia 
The search for approaches to protect the heart against ischemia during coronary occlusion 
has been going on for half a century in both clinical settings and basic research. In the 
current session, we will describe these approaches from the earliest efforts to limit 
myocardial infarct size to the cutting edge of stem cell therapy.  
1.3.1 Clinical Treatment 
1.3.1.1 First line 
Myocardial infarction is a medical emergency which demands immediate attention and 
activation of the emergency medical services. Oxygen, aspirin (antiplatelet drug), 
glyceryl trinitrate (prodrug of NO) and morphine (analgesia), hence the popular MONA 
(morphine, oxygen, nitro, aspirin), are the first line drugs recommended to be 
administered as soon as the symptoms occur (Antman et al., 2004). Once diagnosed as 
myocardial infarction, the patient is often given other pharmacologic agents, including 
beta blockers, anticoagulation (typically with heparin), and possibly additional 
antiplatelet agents such as clopidogrel (Antman et al., 2004). These agents are typically 
not started until the patient is evaluated by an emergency room physician or under the 
direction of a cardiologist.  
1.3.1.2 Reperfusion therapy 
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The ultimate goal of the management in the acute phase of myocardial infarction is to 
salvage as much myocardium as possible and prevent further infarction. Timely 
reperfusion of coronary flow facilitates cardiomyocyte salvage and decreases cardiac cell 
death. Modalities for reperfusion include thrombolysis, percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG). 
Thrombolytic therapy achieves reperfusion by lysing the thrombi in the infarct artery. 
The effectiveness of thrombolytic therapy is determined by the timing of administration 
of thrombolytic agents. The best results are always observed when the thrombolytic agent 
is used within two hours of the onset of symptoms (Boersma et al., 1996). After 12 hours, 
associated risks like intracranial or systemic bleeding outweigh any benefit (Late, 1993). 
An ideal thrombolytic drug would lead to rapid reperfusion, have a high sustained 
patency rate, be specific for recent thrombi, be easily and rapidly administered, and create 
a low risk for intra-cerebral and systemic bleeding (White and Van de Werf, 1993). 
Currently available thrombolytic agents are streptokinase, urokinase, and alteplase 
(recombinant tissue plasminogen activator).  
Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty 
or simply angioplasty, is a surgical procedure to treat the blocked coronary arteries by 
inflating a balloon within the artery to crush the thrombus. The procedure involves 
performing a coronary angiogram to determine the location of the blocked vessel, 
followed by balloon angioplasty to compress the plaque, and implantation of stents to 
prop the vessel open. The benefit of a prompt expertly-performed PCI over thrombolytic 
therapy has been well established (Keeley et al., 2003; Grines et al., 1993). However, 
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logistic and economic obstacles seem to hinder a more widespread application of PCI 
(Boersma et al., 2006).  
Coronary artery bypass graft surgery is another important approach to improve the 
blood supply to the blocked myocardium. During the surgery, an artery or vein from 
elsewhere in the patient’s body is grafted to the coronary artery to bypass narrowings or 
occlusions. Several arteries and veins can be used; however the left internal thoracic 
artery, usually grafted to the left anterior descending coronary artery (LAD), have been 
demonstrated to last longer than great saphenous vein grafts (Raja et al., 2004).  
Emergency CABG is less common than PCI for the treatment of an acute myocardial 
infarction. However, in patients with two or more coronary arteries affected, bypass 
surgery is superior to PCI in terms of long-term survival rates (Hannan et al., 2005).  
Because irreversible injury occurs within 2–4 hours of the infarction, there is a 
limited time window for reperfusion to produce beneficial results. If attempts to restore 
the blood flow are initiated after a critical period of only a few hours, the result is 
reperfusion injury instead of amelioration (Faxon, 2005). Moreover, reperfusion is unable 
to reverse the developed tissue damage. The lost cardiomyocytes will be replaced by a 
collagen scar that is not contractible and permanently impairs the pump function. 
Accordingly, intense interest has been directed to investigate the application of stem cell 
on the repair of heart damage. The present course of this pioneering work will be briefly 
reviewed in the following session.  
1.3.1.3 Stem cell therapy under investigation 
It is traditionally hold that the heart muscle itself has no housekeeping mechanism to 
repair any minor damage, given that the number of myocytes undergoing proliferation is 
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too low if myocytes proliferation were to act as an effective repair mechanism. Stem cell, 
with its ability to self-renew and to form any fully-differentiated cell of the body, 
provides the possibility of repairing end organ damage, particularly the heart that has 
undergone myocardial infarction.  
Several studies have suggested that bone marrow derived progenitor cells were able 
to repair the hearts of animals after myocardial injury (Tomita et al., 1999; Toma et al., 
2002; Orlic et al., 2001). In one report, bone-marrow-derived cells were injected directly 
into the heart of the mouse after myocardial infarction was induced (Orlic et al., 2001). 
Newly formed myocardium composed of proliferating myocytes and vascular structures 
was found to occupy 68% of the infarcted portion of the ventricle 9 days after 
transplanting the bone marrow cells. Using immunofluorescence techniques the 
investigators showed that these primitive bone-marrow-derived cells had undergone a 
process of differentiation that led them to express various markers specific to 
cardiomyocytes. This is supported by several other works suggesting that adult stem cells, 
in particular those derived from bone marrow, were capable of targeting the site of 
myocardial injury as well as undergoing differentiation into cardiomyocytes (Jackson et 
al., 2001; Beltrami et al., 2003).  
These initial findings in animal models have prompted a series of clinical studies in 
human beings. Several groups have independently reported improvement in cardiac 
function in patients treated with stem cells derived from their own bone marrow after a 
myocardial infarction (Assmus et at., 2002; Strauer et al., 2002; Wollert et al., 2004). The 
delivery route of progenitor cells included intracoronary, percutaneous intramyocardial 
and direct intramyocardial at the time of coronary artery bypass graft. Importantly, most 
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of these studies reported few side-effects. However, a failure to explain the action 
mechanism underlying the improvement in cardiac function has provoked concerns. 
Moreover, these trials so far have not been double-blind randomized. Further definitive 
clinical studies are essentially necessary, especially randomized controlled trials (Mathur 
and Martin, 2004). The benefit of this novel approach still needs to be confirmed and 
optimized before it can be applied to treating patients with ischemic heart disease. 
1.3.2 Ischemic Preconditioning (IP) 
With exception of reperfusion therapy, most early attempts to salvage the myocardium 
during acute myocardial infarction have failed to directly reduce infarct size (Przyklenk 
and Kloner, 1998). The first indication that the heart can adapt itself after repeated 
ischemic stress was demonstrated in porcine myocardium, where lactate release in a 
subsequent ischemia/reperfusion (I/R) episode was significantly lower compared with 
lactate release in the first episode of I/R (Verdouw et al., 1979). In 1986 Murry and his 
colleagues published a landmark article in which they documented that four repetitive 5-
min of regional ischemia induced an extremely powerful protection against a subsequent 
lethal ischemia in anesthetized dogs. Infarct size was limited to 25% of that seen in the 
control group after 40 min of sustained ischemia (Murry et al., 1986). The investigators 
named this cardiac warm-up phenomenon as "ischemic preconditioning" (IP). 
Subsequently, numerous studies using various models (e.g., liver, kidney, brain, and 
endothelial cells) showed that short period(s) of ischemia or anoxia could allow tissues to 
survive subsequent ischemia that would have otherwise been lethal (Sanada and kitakaze, 
2004). Understanding this natural protection has since become one of the major targets in 
search for preventions against ischemic damages. 
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While initial studies demonstrated that ischemic preconditioning could protect the 
heart against sustained ischemia that occurred soon after preconditioning, Kuzuya et al. 
(Kuzuya et al., 1993) and Marber et al. (Marber et al., 1993) independently reported in 
1993 that the cardioprotective effect of ischemic preconditioning was still detectable 24 
hours after preconditioning. Kuzuya’s group (Kuzuya et al., 1993) also found that the 
infarct-limiting effect of preconditioning was lost between 3 and 12 hours after a brief 
period of ischemia, which suggested that there were two separate periods of 
cardioprotection afforded by ischemic preconditioning. They named them the ‘‘first 
window’’ and ‘‘second window’’ respectively. The first window of the protection, often 
referred to as classical or early phase, develops as early as few minutes after the 
preconditioning stimulus and lasts only 1–2 hours (Murry et al., 1986). The second 
window, also known as the late or delayed phase, develops more slowly, 12–24 hours 
after the preconditioning stimulus, but lasts for 3–4 days (Kuzuya et al., 1993) (Marber et 
al., 1993). The mechanisms of these two phases are different. The first phase of 
protection is initiated by posttranslational modifications of proteins that are already 
present, whereas the second phase is mediated by synthesis of de novo proteins (Bolli, 
2000);  The early phase depends on reactions that occur very rapidly, such as activation 
of ion channels or phosphorylation of enzymes, whereas the late phase involves processes 
that take far longer to occur such as modulation of the genes regulating channel proteins, 
receptor, enzymes, molecular chaperon proteins, or immune factors (Sanada and kitakaze, 
2004). However, these two types of cardioprotection seem to share certain triggers, 




1.3.2.1 Cellular mechanisms of the early phase of IP 
1.3.2.1.1 Adenosine, bradykinin and opioids  
In 1991, Liu et al. (Liu et al., 1991) first discovered that stimulation of the Gi-coupled 
adenosine A1 receptor was necessary to trigger IP’s protection. They used a rabbit model 
to show that administration of adenosine receptor antagonist, 8-psulfophenyl theophylline 
(8-SPT), prior to sustained ischemia was able to abolish the protective effect of IP. 
Infusion of adenosine or A1-specific agonist reproduced the protection afforded by IP. 
Liu proposed that endogenous adenosine released during IP results in the preconditioned 
phenotype. Two other endogenously released trigger substances, bradykinin (Wall et al., 
1994) and opioids (Schultz et al., 1995), were subsequently found to be involved in IP 
and appeared to work in parallel. Inhibition of any one of these three receptors blocked 
IP’s protection from a single preconditioning cycle. However, the protection could again 
be realized if the number of preconditioning cycles was increased. This led Goto et al. 
(Goto et al., 1995) to suggest that the three receptors had an additive effect required to 
reach a hypothetical protective threshold. Increase in brief ischemia/reperfusion cycles 
released more trigger substances so that two receptors could eventually reach the 
protective threshold even when the third one was inhibited.  
1.3.2.1.2 Protein Kinase C (PKC) 
The multiple trigger theory mentioned above requires that all triggers converge on a 
common target. In 1994, Ytrehus et al. (Ytrehus et al., 1994) found that inhibition of PKC 
abolishes the protection induced by ischemic preconditioning or by pretreatment with 
adenosine. It was later discovered that the cardioprotection afforded by two other trigger 
substances, bradykinin (Goto et al., 1995) and opioids (Miki et al., 1998), could also be 
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blocked by PKC inhibitors. These results suggest that PKC is a strong candidate for the 
common target and plays a pivotal role in the IP’s cardioprotection.  
The PKC family consists of 12 closely related Ser/Tre kinases, classified into three 
distinctive subfamilies. Classical PKCs (cPKC) include PKC α, β1, β2 and γ isoforms, and 
require both Ca2+ and lipids (i.e. phosphatidylserine, PMA and/or diacylglycerol) for their 
activation. Novel PKC isoforms (nPKC), which include PKC δ, ε, η, θ and µ, are not 
sensitive to calcium, but still require lipids for their activation. The subfamily of atypical 
PKC isoforms, PKC ζ and λ, are not activated by Ca2+, diacylglycerol or PMA and their 
regulation is more complicated. The number and levels of PKC isozyme expression 
varies in different tissues and species and changes with developmental stage of the 
animal. 
Early studies on the role of PKC in ischemic preconditioning mainly relied on the 
pharmacological manipulation with PKC inhibitors and stimulators. In an in vivo study 
performed by Speechly-Dick and colleagues (Speechly-Dick et al., 1994), the PKC 
inhibitor chelerythrine, administered after a preconditioning stimulus, abolished 
protection conferred by IP, and caused an increase in infarct size. In the same study, PKC 
stimulator 1,2-dioctanoyl-sn-glycerol, administered prior to sustained ischemia, 
significantly reduced infarct size. 
A large body of data supporting the PKC hypothesis has been obtained in the isolated 
rat heart subjected to sustained global ischemia (Mitchell et al., 1995; Hu and Nattel, 
1995). In this model, functional recovery during reperfusion is typically chosen as the 
index of damage caused by sustained ischemia, and to evaluate the protective effect of IP. 
For example, Mitchell et al. showed that preconditioning with brief episode of I/R 
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significantly increased functional recovery at 40 min after relief of a 20 min period of 
global ischemia (Mitchell et al., 1995). The PKC inhibitors chelerythrine and 
staurosporine abolished this protective effect, while the diacylglycerol analogue 1-
stearoyl-2-arachidonoyl glycerol mimicked the benefits of ischemic preconditioning. 
Moreover, immunoblotting for PKC isoforms showed that two major isoforms in rat heart, 
PKCδ and PKCε, both translocated during brief episodes of transient ischemia from 
cytosol into membrane and nuclear compartments. 
The role of PKC in ischemic preconditioning has been evaluated in a diverse array of 
models, species and protocols. Most of the results were obtained using pharmacological 
approach, i.e. by administering PKC inhibitors and/or activators. Unfortunately, these 
inhibitors or activators are isoform-nonspecific, which makes it difficult to single out the 
isoforms that are responsible for the IP cardioprotection. Immunoblotting represents an 
alternative to pharmacological and biochemical methods. By assessing subcellular 
distribution of PKC isoforms, the involvement of a given isoform can be determined. A 
better solution is to develop isoform-specific inhibitors and activators. In a study 
conducted by Gray et al., isoform-specific inhibition of PKCε has been successfully 
employed. In a cell culture model of hypoxic preconditioning, they found that specific 
inhibitor of PKCε (i.e. ε-VI-2 peptide) abolished the protection induced by hypoxic 
preconditioning and phorbol ester (Gray et al., 1997). This isoform specific modification 
allows researchers to identify the particular isoforms that are necessary for the 
cardioprotection to occur. 
1.3.2.1.3 ATP-sensitive-potassium channel (KATP) 
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Investigation of KATP channels has a longer history than studies on ischemic 
preconditioning. In 1983, Noma (Noma, 1983) first reported the existence of these 
channels in the myocardium. The cardiac KATP channel is composed of four Kir6.2 
subunits (inwardly rectifying potassium channel) and four SUR2A subunits (sulfonylurea 
receptor) and is modulated by Mg2+ and ATP (Snyders, 1999). Opening of the surface or 
sarcolemmal KATP channel (sarcoKATP) was proposed to produce cardioprotection via 
shortening of phase 3 repolarization of the cardiac action potential and membrane 
hyperpolarization, both of which would lead to reduced calcium overload during 
ischemia/reperfusion and a preservation of ATP (Noma, 1983). These phenomena 
resemble the acute cardiac responses and cardioprotection afforded by ischemic 
preconditioning. Indeed, a number of early studies have presented strong evidence for a 
role for sarcoKATP in mediating IP, with infarct size reduction as the end point to describe 
the cardioprotective effect. These include those reported by Yao and Gross (Yao and 
Gross, 1994) and Schulz et al. (Schulz et al., 1994), who showed an association between 
action potential shortening and IP, and the study of Haruna et al. (Haruna et al., 1998), 
who showed digoxin, an inhibitor of Na+-K+ ATPase, blocked the cardioprotective effect 
of IP by indirectly desensitizing KATP channels. Another study using molecular 
techniques shed some light on the role of KATP in alleviating calcium overload during 
ischemia. Jovanovic et al. (Jovanovic et al., 1986) found that in KATP-deficient COS-7 
cells, marked calcium loading occurred when these cells were exposed to 3 minutes of 
chemically-induced hypoxia. However, when they cotransfected the cells with both 
subunits of the sarcoKATP channel, SUR2A and Kir6.2, the addition of the KATP opener 
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pinacidil attenuated the calcium loading. Similar results were obtained with pinacidil in 
cardiac myocytes expressing the native sarcoKATP channel.  
In 1991, Inoue et al. (Inoue e tal., 1991) found that not only the cell membrane but 
also the inner mitochondrial membrane possessed ATP-sensitive inward rectifier activity, 
and they suggested the existence of “mitochondrial KATP channels” (mitoKATP). It is 
thought that a beneficial effect may result from K+ entry through mitoKATP and 
intramitochondrial depolarization. This effect would reduce mitochondrial calcium 
overload and cause moderate matrix swelling, which leads to slowing of ATP synthesis 
and accelerated mitochondrial respiration (Holmuhamedov et al., 1998). Moreover, the 
reactive oxygen species (ROS), which are transiently generated by opening of the 
mitoKATP channels, is able to activate downstream cascades and confer the 
preconditioning effect (Pain et al., 2000). The mitoKATP could thus be involved in acute 
IP as either a trigger or an end effector, or both.  
Thereafter, the contribution of mitochondrial and sarcolemmal KATP channels to IP-
induced cardioprotection has been studied extensively. The effect that had been 
considered to be related to sarcolemmal KATP channels, were found to be actually 
mediated by mitochondrial KATP channels (Liu et al., 1999). However, some concerns 
have been raised over those studies on the role of mitoKATP channels in IP. Firstly, the 
structure of mitoKATP is still largely unknown. It is now thought that mitoKATP might not 
include the Kir 6.1 or Kir 6.2 subunits, which are common to sarcolemmal and other 
KATP channels (Suzuki et al., 2002). Secondly, the only tool drugs available to 
pharmacologically modulate mitoKATP channels (diazoxide as an opener and 5-
hydroxydecanoate [5-HD] as an inhibitor) also have direct effects on cellular respiratory 
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metabolism (Dzeja et al., 2003; Hanley et al., 2003). Thirdly, some recent studies using 
big animal models have failed to show complete modulation of the cardioprotective effect 
of ischemic preconditioning by these two drugs (Sanada et al., 2001a; Schwartz et al., 
2002).  
It is not clear why these discrepancies exist, but some investigators have suggested 
that opening of sarcolemmal KATP channels may be more important in the beating hearts 
to limit stunning, while in in vitro experimental conditions opening of mitoKATP appears 
to limit cell death (Gross and Peart, 2003). The actual cardioprotective role of these 
channels still needs to be investigated further.  
1.3.2.1.4 The mitogen-activated protein kinase (MAPK) 
Mitogen-activated protein kinase (MAPK) are serine-threonine protein kinases that are 
activated by diverse stimuli ranging from cytokines, growth factors, neurotransmitters, 
hormones, cellular stress, and cell adherence. They function in a three-tier module 
comprising of a MAPK kinase kinase, a MAPK kinase and a MAPK. The mammalian 
MAPK can be subdivided into five families: 42 and 44-kDa extracellular signal-regulated 
kinase (Erk1/2), p38, the c-Jun NHP2 terminal kinase (JNK), Erk 3/4 and Erk 5 
(Widmann et al., 1999). 
The role of Erk1/2 as a potential mediator of IP has been controversial, with the 
majority of studies supporting its role in the IP’s cardioprotection (Hausenloy and Yellon, 
2006). In response to preconditioning stimulus, Erk1/2 was found to redistributes to the 
nucleus, intercalated discs, cytosol and mitochondria. Erk1/2 can phosphorylate and 
inhibit GSK-3β (Eldar-Finkelman et al., 1995), the consequence of which is inhibition of 
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mPTP in different settings of cardioprotection (Juhaszova et al., 2004). Thus it is worthy 
to investigate whether Erk1/2 mediates IP’s cardioprotection by inhibiting mPTP opening.  
Weinbrenner et al. (Weinbrenner et al., 1997) were the first to report that IP caused 
p38MAPK activation during ischemia in preconditioned rabbit heart. However, 
p38MAPK was not activated during ischemia in the control group. Contradictory results 
were obtained in 1999 by in vivo (Ma et al., 1999) and in vitro (Mackay and Mochly-
Rosen, 1999) studies suggesting that p38MAPK activation could promote ischemic 
damage. Interestingly, in the latter study, prolonged ischemia was found to induce 
biphasic activation of p38MAPK in rat cardiomyocytes, with a transient peak occurring 
within minutes and followed by a sustained activation after 2h (Mackay and Mochly-
Rosen, 1999). Another study performed by Sanada revealed that IP caused a transient but 
strong activation of p38MAPK. Treatment with SB 203580, a selective p38MAPK 
inhibitor, during IP blunted the infarct size-limiting effect of IP, while, conversely, the 
presence of the inhibitor during sustained ischemia partially mimicked the protection of 
IP (Sanada et al., 2001b). This observation led to the hypothesis that p38MAPK 
activation has opposing effects; that is, transient activation during IP prevents ischemic 
injury, while continuous activation during sustained ischemia exacerbates it.  
1.3.2.1.5 Phosphoinositide 3 kinase (PI3-K) and Akt 
PI3-K, the kinase phosphorylating the plasma membrane lipid phosphatidyl-inositol-4,5-
bisphosphate to phosphatidyl-inositol-3,4,5-triphosphate, is implicated in a diverse group 
of cell functions, including cell growth, cell differentiation, cell survival and intracellular 
trafficking. Many of these functions are related to its ability to activate Protein Kinase B 
(PKB, also called Akt) (Cantley, 2002). 
22 
 
In 2000, Tong et al. (Tong et al., 2000) first demonstrated that IP protects the heart by 
activating the PI3K–Akt pathway and were later supported by several other studies 
(Mocanu et al., 2002; Yamaura et al., 2003). Inhibition of PI3-K was shown to attenuate 
IP’s cardioprotective effect and also block the phosphorylation of Akt following IP. Akt 
is known to be able to activate anti-apoptotic pathways (Hausenloy and Yellon, 2004). A 
recent study by Davidson et al. demonstrated that over-expressing Akt protected cells 
against oxidative stress by inhibiting mPTP opening (Davidson et al., 2006). 
1.3.2.2 Cellular mechanisms of the late phase of IP 
The late phase of ischemic preconditioning provides far more prolonged cardioprotection 
than the early phase (48-72 hours versus 2 to 3 hours), which gives rise to the notion that 
the late phase may ultimately have greater clinical usefulness.  
1.3.2.2.1 Adenosine 
The concept that adenosine released during the brief ischemia stimulus triggers the 
development of delayed protection was first proposed by Baxter et al. (Baxter et al., 1994) 
and subsequently expanded by the same group (Baxter and Yellon, 1997a; Dana et al., 
1998) and others (Auchampach et al., 1999; Takano et al., 1999). Activation of adenosine 
receptors has been reported to provide delayed protection only against myocardial 
infarction but not against myocardial stunning or arrhythmias (Maldonado et al., 1997; 
Auchampach et al., 1999). And such delayed protection can be triggered by activation of 
either adenosine A1 or A3 receptors (Auchampach et al., 1999; Takano et al., 1999). 
However, it is not clear whether only one or both of these adenosine receptor subtypes 
contributes to triggering delayed IP, because 8-psulfophenyl theophylline, the only 
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adenosine receptor antagonist shown to block the development of late IP (Baxter et al., 
1994), is not selective between A1 and A3 receptors. Studies have shown that selective 
stimulation of adenosine A1 receptors activates p38MAPK-HSP27 pathway via a PKC-
dependent mechanism (Dana et al., 2000b) and increases the synthesis of manganese 
superoxide dismutase (Mn–SOD) (Dana et al., 2000a), while the role of A3 receptors is 
yet to be established. 
1.3.2.2.2 Reactive Oxygen Species (ROS) 
ROS includes oxygen ions, free radicals, and peroxides. They are highly reactive due to 
the presence of unpaired valence shell electrons. While a large burst of ROS results in 
cell damage, moderate release of ROS can act as an alarm to warn the myocardium to 
switch to a defensive phenotype.  An obligatory role of ROS in the delayed protection 
induced by IP was first discovered by Sun et al. (Sun et al., 1996). These investigators 
demonstrated in conscious pigs that the administration of a combination of antioxidants 
(superoxide dismutase [SOD] plus catalase plus mercaptopropionyl glycine [MPG]) 
during the initial ischemic challenge prevented the development of late protection against 
stunning. MPG has also been found to prevent the late protection against infarction, 
arrhythmias (Yamashita et al., 1998), and coronary endothelial injury (Kaeffer et al., 
1997). In contrast, intracoronary infusion of an ROS-generating solution in rabbits elicits 
a late IP-like response (Takano et al., 1997). These findings provided strong evidence that 
sublethal oxidative stress is essential to initiate the protection observed in the late phase 
of IP.  
1.3.2.2.3 Nitric Oxide (NO) 
24 
 
Nitric oxide (NO) is an endogenous vessel relaxant that was initially identified as 
endothelium-derived relaxation factor (EDRF). It is generated from the amino acid L-
arginine by various nitric oxide synthase (NOS). There are 3 forms of NOS: endothelial 
(eNOS), neuronal (nNOS), and inducible (iNOS), each with separate functions. The two 
isotypes present in the cardiovascular system are eNOS and iNOS.  
The first indication that NO triggers late IP was provided by a study in which 
administration of Nw-nitro-L-arginine (L-NA), a nonselective inhibitor of all NOS 
isoforms, before preconditioning stimulus blocked the development of delayed protection 
against myocardial stunning (Bolli et al., 1997a). A subsequent study demonstrated that 
NO is also necessary to trigger delayed protection against myocardial infarction (Qiu et 
al., 1997). Importantly, exposure to exogenous NO is sufficient to reproduce late 
protection against both myocardial stunning and infarction that is observed during the late 
phase of IP (Takano et al., 1998b). 
NO plays a dual role in the genesis of late cardioprotection of IP, acting initially as a 
trigger and subsequently as a mediator. Immediately after preconditioning stimulus, there 
is an increase in eNOS activity in the myocardium (Xuan et al., 2000). The enhanced 
biosynthesis of NO by eNOS is important to trigger the development of the delayed 
cardioprotection, which can be abrogated by non-selective NOS inhibitor but not by 
relatively selective inhibitors of iNOS applied before the preconditioning stimulus (Bolli 
et al., 1997b).  However, 24 hours after the brief I/R stimulus, iNOS seems to take over 
and mediate the late protection. Evidence was first provided by two studies in conscious 
rabbits, in which the delayed protection against both myocardial stunning (Bolli et al., 
1997b) and infarction (Takano et al., 1998a) was abrogated by administration of 
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relatively selective iNOS inhibitors 24h after preconditioning, just before the lethal 
ischemia. Guo et al. (Guo et al., 1999) later demonstrated that the late phase of IP is 
associated with upregulation of myocardial iNOS (whereas eNOS remains unchanged) 
and that targeted disruption of the iNOS gene eliminated the delayed infarct-sparing 
effect. Taken together, the two isoforms of NOS are sequentially involved the late phase 
of IP, with eNOS generating the NO that initiating the development of IP response on day 
1 and iNOS generating the NO that protects against recurrent ischemia on day 2 (Bolli, 
2000).  
1.3.2.2.4 PKC 
In 1995, Baxter first demonstrated the essential role of PKC in the late phase of IP with a 
study in which the delayed infarct-sparing effects of IP in rabbits were abrogated by 
pretreatment with the PKC inhibitor chelerythrine (Baxter et al., 1995). Conversely, 
administration of the PKC activator dioctanoyl-sn-glycerol induced cardioprotection 24 
hours later (Baxter et al., 1997b). Subsequent studies revealed that IP caused selective 
translocation of PKCε and PKCη but did not affect the other 8 isoforms expressed in the 
rabbit heart and did not significantly change total PKC activity (Ping et al., 1999b). In the 
same model, pretreatment with the PKC inhibitor chelerythrine at doses that have 
previously been shown to block IP’s protection blocked the translocaiton of PKCε (Ping 
et al., 1999b), whereas the same inhibitor at a 10-fold lower dose shown to only block the 
translocation of PKCη failed to abrogate the late protection of IP (Qiu et al., 1998). These 
findings suggest that activation of PKC after ischemic preconditioning is isoform 
selective and ε seems to be the specific PKC isozyme responsible for the development of 
delayed protection in this setting. The IP-induced activation of PKCε is likely to be 
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caused by the generation of NO during the initial ischemic stress according to Ping’s 
study, where they found that such activation was blocked by pretreatment with L-NA 
(Ping et al., 1999a). In the same study, they also observed that administration of NO 
donors in the absence of ischemia induced a selective activation of PKCε to an extent 
comparable to that induced by IP, while coadministration of chelerythrine blocks both the 
activation of PKCε and the delayed protection elicited by the NO donors (Ping et al., 
1999a).  
Other Preconditioning studies have implicated PKC-α, PKC-δ, and PKC-ε in the rat 
heart (Yoshida et al., 1997), and PKC- α in the dog heart (Kitakaze et al., 1997). 
Interestingly, in an isolated rat heart model, PKC-δ and PKC-ε are demonstrated to play 
opposing roles in cardioprotection, with activation of the former being detrimental and 
activation of the latter being protective (Inagaki et al., 2003). In another study using a 
mouse model, transgenic expression of constitutively-activated PKCε in the heart was 
shown to be able to recapitulate both the signaling events and the late protection of IP 
(Ping et al., 2000).  
1.3.2.2.5 KATP channel 
Pharmacological studies have provided evidence that opening of KATP channels is 
necessary for the delayed infarct-sparing effects induced by ischemic preconditioning 
(Bernardo et al., 1999; Takano et al., 2000), adenosine A1 and A3 receptor agonists 
(Takano et al., 1999), and opioid receptor agonists (Fryer et al., 1999). These diverse 
preconditioning stimuli converge on KATP channels, suggesting that the activity of these 
channels may be a common distal effector of delayed protection against cell death. 
However, the IP-induced late protection against stunning does not appear to require KATP 
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channel activity (Takano et al., 1999). The different role of KATP channels in late IP 
against stunning versus against infarction provides evidence that different mechanisms 
underlie these two forms of cardioprotection.  
Major issues that remain to be elucidated are the identity of the KATP channels 
involved in the late phase of IP (i.e., sarcolemmal versus mitochondrial) and the 
mechanism whereby their opening confers protection. Given the limitations of the 
available pharmacological tools, it has been suggested that molecular approaches such as 
gene targeting and transgenesis will be required to definitively assess the role of 
mitochondrial versus sarcolemmal KATP channels (Bolli, 2000).  
1.3.2.2.6 Transcription factors 
Transcription factors govern the expression of the cardioprotective genes responsible for 
late IP. The first transcription-regulatory element identified in the late IP signaling 
mechanisms was nuclear factor-kB (NF-kB) (Xuan et al., 1999), which is known to be a 
major modulator of iNOS, COX-2, and aldose reductase gene expression. Using 
conscious rabbits, Xuan and colleagues found that IP induced rapid activation of NF-kB. 
Inhibition of NF-kB with diethyldithiocarbamate completely abrogated the 
cardioprotective effects observed 24 hours later. They further demonstrated that the IP-
induced activation of NF-kB was blocked by pretreatment with L-NA (NOS inhibitor), 
MPG (antioxidant), chelerythrine, and LD-A (protein tyrosine kinase [PTK] inhibitor), all 
given at doses previously shown to block late IP.  This finding indicates that the cellular 
mechanism whereby IP activates NF-kB involves the formation of NO and ROS and the 
subsequent activation of PKC and PTK-dependent signaling events. Thus, NF-kB appears 
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to be a common downstream pathway though which multiple signals elicited by ischemic 
stress (NO, ROS, PKC, and PTKs) act to induce gene expression in the heart.  
1.3.2.2.7 Cyclooxygenase-2 (COX-2) 
Cyclooxygenase (COX) is the rate-limiting enzyme in prostaglandin (PG) synthesis, 
catalyzing the conversion of arachidonic acid to PGH2 (Smith et al., 1996). Two distinct 
COX isoforms have been characterized so far: COX-1, which is present in most cells and 
is responsible for constitutive prostanoid formation, and COX-2, which is inducible and 
becomes abundant in activated macrophages and other cells at sites of inflammation.  
Induction of COX-2 was generally thought detrimental. However, the role of COX-2 
in cardiovascular system has been found to be beneficial. Recent studies have 
demonstrated that ischemic preconditioning upregulates the expression and activity of 
COX-2 in the heart 24h after preconditioning, concomitant with an increase in the 
myocardial levels of PGE2, 6-keto-PGF1α (the stable metabolite of PGI2), and (to a lesser 
extent) PGF2α (Shinmura et al., 2000). Administration of 2 unrelated COX-2-selective 
inhibitors (NS-398 and celecoxib) 24 hours after IP abolishes the increase in prostanoids 
and, at the same time, completely blocks the cardioprotective effects of late IP against 
both myocardial stunning and infarction. These observations identify COX-2 as a 
cardioprotective protein and strongly point to PGE2 and/or PGI2 as the likely effectors of 
COX-2–dependent protection. Subsequent studies by the same group further addressed 
the mechanism underlying the regulation of COX-2 by IP (Shinmura et al., 2002). Using 
conscious rabbit model, they found that induction of COX-2 protein expression in 
preconditioned myocardium requires PKC-, Src/Lck PTK-, and NF-κB-dependent 
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signaling. On the other hand, iNOS-derived NO was required for the activity of newly 
synthesized COX-2 following IP. 
1.3.2.2.8 Heat shock protein (HSP) 
Heat shock proteins (HSP) are a group of highly conserved proteins whose expression is 
increased when the cells are exposed to elevated temperatures or other stress. Each HSP 
is named according to its molecular weights. The best characterized HSPs, hsp90, hsp70 
and hsp65, are induced in response to heat in all organisms studied from bacteria to 
human. 
In 1991, Knowlton et al. first reported the expression of HSP in rabbit after brief 
ischemia challenge (Knowlton et al., 1991). Marber et al. confirmed this finding (Marber 
et al., 1993) and further demonstrated in a later study that there is a correlation between 
the amount of hsp70 induced and the ability to limit infarct size (Marber et al., 1994). 
This led to the hypothesis that the protection of late IP is mediated by these chaperon 
proteins. In 1995–1996, several groups successfully generated transgenic mice that over-
expressed hsp70 in the heart and other organs (Marber et al., 1995; Plumier et al., 1995; 
Radford et al., 1996). In all cases, these groups were able to demonstrate that such over-
expression of hsp70 protected the heart against ischemia damage using a variety of 
endpoints such as infarct size, creatine kinase release, recovery of high energy phosphate 
stores, and correction of metabolic acidosis. 
Recently, another member of HSP, hsp27 has been suggested to participate in the late 
protection of IP as a downstream target of p38MAPK (Nakano et al., 2000; Huot et al., 
1997; Hedges et al., 1999). The translocation of hsp27 from cytosol to myofibril or 
nucleus may prevent actin fragmentation (Huot et al., 1996) or microtubule degradation 
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(Bluhm et al., 1998). On the other hand, hsp27 prevents the interaction of Apaf-1 with 
procaspase-9 through binding to cytochrome c (Garrido et al., 1999). Both of these 
actions can ameliorate or delay ischemic cell death. 
1.3.3 Pharmacological preconditioning 
Despite the powerful protection provided by ischemic preconditioning, the clinical 
implement of this approach faces practical problems. Because brief ischemia challenge 
must precede lethal ischemia to achieve cardioprotection, induction of preconditioning 
ischemia doesn’t serve as a realistic therapeutic strategy for patients with ischemic heart 
disease. However, if the signaling mechanisms underlying IP can be determined, more 
simple and effective therapeutic intervention can be developed accordingly. Considerable 
progress has been made to understand the signaling mechanism and to identify the 
substances that are capable of duplicating the cardioprotection induced by IP. These 
substances can be divided into two categories: naturally occurring but often noxious 
agents, e.g. endotoxin (Brown et al., 1989), interleukin-1 (Brown et al., 1990), tumor 
necrosis factor-α (Brown et al., 1992), leukemia inhibitory factor (Nelson et al., 1995), 
ROS (Sun et al., 1996),  and clinically applicable drugs including KATP channel opener 
(Sato et al., 2000), NO releasing agents (Takano et al., 1998b), adenosine receptor 
agonists (Baxter et al., 1994), and opioid receptor agonists (Fryer et al., 1999). Most of 
these forms of preconditioning have been shown to protect against lethal 
ischemia/reperfusion injury, and some have been demonstrated to protect against 
reversible postischemic dysfunction (Sun et al., 1996) and endothelial dysfunction 
(Kaeffer et al., 1997). Further efforts should be directed to promote more clinical studies 
based on the evidence from experimental studies in larger animals.  
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1.4 Hydrogen Sulfide (H2S) 
For many decades, H2S has been receiving attention as a toxic gas and environmental 
hazard. Its physiological importance was not recognized until the recent finding that H2S 
occurs naturally in mammalians. This led to the discovery of H2S as the third 
gasotransmitter after NO and CO. In the following content, recent works on H2S will be 
reviewed with an emphasis on its biological effects and its roles in different diseases.  
1.4.1 Physical and chemical properties of H2S 
Hydrogen sulfide (H2S) is a colorless, flammable and water soluble gas with smell of 
rotten eggs. The detectable level of this gas by human olfaction is 400 folds lower than its 
toxic level. In an aqueous solution, H2S is a weak acid which dissociates in the following 
reaction: H2S  H+ + HS-  2H+ + S2-. According to the Henderson–Hasselbach 
equation, it will form approximately 18.5% H2S and 81.5% hydrosulfide anion (HS) in a 
physiological solution (pH 7.4, 37°C) (Dombkowski et al., 2004). H2S is a highly 
lipophilic molecule, which enables it to freely penetrate cells of all types and become 
biologically active.  
1.4.2 Endogenous generation and metabolism of H2S 
It is known that certain bacteria and archae can produce H2S. Recently, mammalian cells 
have also been found to be able to generate and metabolize H2S. For example, the H2S 
concentration in rat serum was reported to be around 46µM (Zhao et al., 2001). A higher 
level of H2S was detected in the brain and reported to be 50~160 µM (Abe and Kimura, 
1996).  However, such remarkably high concentrations of H2S have recently been 
questioned by some reviews (Li and Moore, 2008; Szabó, 2007) and a group of 
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researchers (Whitfield et al., 2008) who failed to detect H2S at micromolar level in the 
blood of a variety of animals. Indeed, the evanescent and reactive nature of this gas 
makes it difficult to accurately measure its concentration in an aqueous solution. A direct, 
reliable and stable means of detection needs to be developed before a conclusion can be 
drawn.  
Despite the discrepancy on the exact concentration of circulating sulfide, two 
pyridoxal-5-phosphate-dependent enzymes have been identified as the endogenous 
synthases of H2S, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE). Both 
of them use L-cysteine as the main substrate and collectively are responsible for the 
majority of H2S production in the body (Stipanuk and Beck, 1982; Erickson et al., 1990; 
Bukovska et al., 1994). The expression of CBS and CSE has been detected in a board 
variety of cell types, including those from liver, kidney, heart, brain, skin fibroblastes, 
and lymphocytes (Wang, 2002). In some tissues, both CBS and CSE contribute to the 
local generation of H2S, whereas in others, one enzyme predominates.  CBS is the 
predominant H2S synthase in the brain and nervous system and is highly expressed in 
liver and kidney, while CSE is primarily expressed in the heart, liver, vascular and non-
vascular muscles.  
H2S in vivo is metabolized by oxidation in mitochondria before it is excreted through 
urine as free or conjugated sulfate (Beauchamp et al., 1984). Nevertheless the mechanism 
of the conversion of sulfide to sulfate or thiosulfate is poorly understood. The role of a 
sulfide oxidase and/ or glutathione has been proposed. A less important metabolic 
pathway involves methylation of sulfide by cytosolic S-methyltransferase. It is worthy of 
note that H2S can also be scavenged by methemoglobin (Beauchamp et al., 1984) or 
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metallo- or disulfide-containing molecules such as oxidized glutathione (Smith and 
Abbanat, 1966). Hemoglobin may act as a common sink for CO, NO and H2S (Wang, 
1998). It interacts with H2S by forming green sulfhemoglobin (Arp et al., 1987). Caution 
should be raised if this sink is saturated by one of the three gases; then its ability to bind 
other gases would be reduced (Searcy and Lee, 1998).   
1.4.3 Biological role of H2S  
1.4.3.1 H2S and the central nervous system (CNS) 
The presence of considerable amounts of H2S and its synthase CBS in the brains of 
several species including humans suggested a role for this gas in CNS function (Kimura, 
2002). H2S has been shown to facilitate induction of hippocampal long-term potentiation 
by increasing the sensitivity of NMDA receptors (Kimura, 2000). Interaction of H2S and 
NMDA receptors possibly involves cAMP-dependent protein kinase pathway, since in 
the same study NaHS increases cAMP levels in neuronal and glial cell lines and primary 
neuron cultures. In addition, H2S was also reported to induce protection against 
glutamate-mediated toxicity in cortical neurons (Kimura et al., 2006) and mouse 
hippocampal cell line (Kimura and Kimura, 2004), perhaps by multiple mechanisms 
including activation of KATP and Cl− channels and elevation of intracellular glutathione 
(Kimura et al., 2006). 
Deranged biosynthesis of H2S has been found to be associated with central nervous 
system diseases, such as stroke (Qu et al., 2006), Down syndrome (Kamoun et al., 2003), 
and perhaps also Alzheimer's disease (Eto et al., 2002). In the rat model of stroke (Qu et 
al., 2006), middle cerebral artery occlusion caused an increase in H2S level in the lesioned 
cortex as well as an increase in the H2S synthesizing activity. In keeping with this, 
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administration of a sulfide donor significantly increased the infarct volume. In subjects 
with Down syndrome, urinary thiosulfate (a metabolite of H2S) and erythrocyte 
sulfhemoglobin levels were both significantly increased compared with diet-matched 
controls (Kamoun et al., 2003). Further studies are warranted to determine whether the 
abnormity of H2S level is a cause or simply a consequence of these diseases.  
1.4.3.2 H2S and inflammation 
Extensive studies have recently been conducted to define the role of H2S in various 
inflammatory diseases. At micromolar concentrations, H2S can induce an upregulation of 
anti-inflammatory and cytoprotective genes including haem oxygenase-1 in pulmonary 
smooth muscle cells in vivo (Qingyou et al., 2004) and in macrophages in vitro (Oh et al., 
2006). H2S also reduces LPS-stimulated TNF-α and NO formation in cultured microglial 
cells (Hu et al., 2006).  In animal models of inflammation, administration of H2S donor 
has been effective in reducing carrageenan-induced paw edema and air pouch-induced 
leukocyte infiltration (Zanardo et al., 2006), the commonly-used systems to test the anti-
inflammatory effects of experimental compounds. The protective effect of H2S was 
attenuated by pretreatment with glibenclamide, suggesting the involvement of KATP 
channels. Several other studies demonstrated that chemically linking an H2S-donor 
species to known anti-inflammatory drugs can improve the therapeutic profile of the 
compound. Using a rat model of endotoxin-induced inflammation, Li and colleagues 
reported that a sulfide-releasing compound, S-diclofenac, enhanced the anti-inflammatory 
effect of the parent molecule and exhibited less gastric toxicity (Li et al., 2007). Similarly, 
in the study by Distrutti et al., the H2S-releasing derivative of mesalamine demonstrated 
superior anti-inflammatory and antinociceptive efficacy compared with the base 
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mesalamine molecule in the model of postinflammation hypersensitivity (Distrutti et al., 
2006).  
However, it is paradoxical that an upregulation in H2S-synthesizing activity or plasma 
H2S level was observed in a large body of studies using different inflammation models. 
These include carrageenan-induced paw oedema in rats (Bhatia et al., 2005a), a mouse 
model of pancreatitis (Bhatia et al., 2005b), rodent model with endotoxic shock (Collin et 
al., 2005; Li et al., 2005), and a polymicrobial sepsis model in mice with cecal ligation 
and puncture (Zhang et al., 2006). Pharmacological inhibitor of H2S biosynthesis, DL-
propargylglycine (PAG) (Marcotte and Walsh, 1975), was used in some of these studies 
and shown to be able to attenuate the inflammatory responses. In a rat model of 
endotoxemia, PAG prevented the increases in the serum levels of liver and pancreas 
injury markers and reduced the tissue content of myeloperoxidase (Collin et al., 2005). In 
a model of cecal ligation and puncture, PAG treatment reduced tissue neutrophil 
infiltration and improved liver and lung histology (Zhang et al., 2006). In a carrageenan-
induced inflammation model in the rat, PAG treatment dose-dependently reduced paw 
edema and neutrophils infiltration (Bhatia et al., 2005a). 
Interestingly, both inhibitor and donor of H2S were shown to exert beneficial effects 
in the same experimental model of disease, for instance, in the carrageenan paw edema 
model (Bhatia et al., 2005a; Zanardo et al., 2006).  While one study demonstrates anti-
inflammatory effects of H2S (Zanardo et al., 2006), another one argues for a pro-
inflammatory role of H2S in the same model (Bhatia et al., 2005a). A reasonable 
explanation for these conflicting results is that endogenous sulfide at low and high local 
concentrations exert opposing effects, with low concentration preventing and high 
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concentration promoting inflammation. A similar paradox has been previously noted with 
inhibitors versus donors of NO — both of them being effective in the carrageenan paw 
edema models (Handy and Moore, 1998; Fernandes et al., 2002). Clearly, there is an 
exquisite balance and a complex regulation of pathophysiological responses by 
endogenous and exogenous gasotransmitters (Szabó, 2007). 
1.4.3.3 H2S and cardiovascular system 
It was conventionally held that H2S interfered with cardiovascular function as a result of 
the secondary anoxia rather than a direct action of the gas on cardiac myocytes or 
vascular smooth muscle cells (SMCs) (Reiffenstein et al., 1992). However, this view has 
been overturned by the finding of noticeable amount of H2S and its synthase CSE in the 
cardiovascular system.  
As early as in 1997, expression of CSE and endogenous production of H2S have been 
detected in rat portal vein and thoracic aorta (Hosoki et al., 1997). A more recent study by 
Zhao et al. revealed that CSE is the only H2S-generating enzyme in rat mesenteric artery 
and other vascular tissues, with expression levels of CSE mRNA ranked in an order of 
pulmonary artery > aorta > tail artery > mesenteric artery (Zhao et al., 2001). On the other 
hand, Chen et al. found no activity or expression of CBS in human atrium and ventricle 
tissues (Chen et al., 1999). The activity and/or expression of CBS were also lacking in 
human internal mammary arteries, saphenous veins, coronary arteries, or aortic arteries 
(Chen et al., 1999; Bao et al., 1998). Thus, only CSE appears to be responsible for the 
generation of H2S in cardiovascular tissues. 
The effect of H2S on vascular systems has recently been investigated in several in-
depth studies. H2S at physiologically relevant concentrations induces relaxation in portal 
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vein (Hosoki et al., 1997), aorta (Zhao et al., 2001), and mesenteric artery beds of rats 
(Cheng et al., 2004). In one study by Zhao et al. (Zhao et al., 2001), an intravenous bolus 
injection of H2S at 2.8 and 14 µmol/kg body weight provoked a transient decrease in 
mean arterial blood pressure of anaesthetized rats. At the tissue level, H2S induced a 
concentration-dependent relaxation of the phenylephrine (PHE)-precontracted rat aortic 
tissues (IC50, 125 µM). The investigators also provided significant insight into the 
mechanism of the H2S-induced vasorelaxant effect (Zhao et al., 2001). They found that 
when isolated rat aortic tissues were precontracted with 20 or 100 mM KCl, the maximum 
vascular relaxation induced by H2S was 90% and 19%, respectively. This difference in 
relaxation potency of H2S may represent the portion of relaxation possibly mediated by 
potassium conductance. Furthermore, the effect of H2S on aortic tone was only 
antagonized by the blocker of KATP channel, glibenclamide, but not blockers of other 
types of potassium channels, indicating that the vasorelaxant effect of H2S was KATP-
dependent. Meanwhile, they demonstrated that H2S directly increased KATP channel 
currents and hyperpolarized membrane in isolated SMCs. Taken together, all these lines 
of evidence point to that H2S is an important endogenous vasorelaxant factor and gaseous 
opener of KATP channels in vascular SMCs. 
In spite of the detection of CSE in myocardial tissues, the effect of H2S on heart was 
relatively less known. Geng et al. observed a negative inotropic effect of H2S in both in 
vitro and in vivo experiments, and the effect could partly be blocked by glibenclamide 
(Geng et al., 2004). As discussed by the investigators, in addition to direct effect of H2S 
on myocardium, the cardiac contraction could also be affected by its peripheral vascular 
effect, because H2S dilated arteries and veins, reducing central venous pressure, which 
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could result in a decrease of the venous return and reduction of cardiac pre- and post-
loads. Although this study is suggestive of a role for H2S in regulating cardiac function, 
the significance of these observations should further be determined in pathological 
settings.  
1.4.3.4 Other effects of H2S 
Sulfide may also have therapeutic potential in the areas of angiogenesis and wound 
healing. Studies have demonstrated that H2S stimulates endothelial cell growth, adhesion, 
migration and promotes scratched wound healing in vitro, probably through a PI3-K/Akt 
pathway (Cai et al., 2007). Intraperitoneal injection of NaHS for 7 days significant 
increases neovascularization in rats. Other studies showed that sulfide donors promote 
gastric ulcer healing in rodent models (Wallace et al., 2007; Yonezawa et al., 2007), but 
the effect did not appear to depend on NO synthesis or KATP opening.  
1.4.3.5 Interaction of H2S and other gasotransmitters 
H2S is the third gasotransmitters together with NO and CO. It is not surprising that these 
mediators interact with one another in regulating cell functions, cardiovascular responses 
and inflammatory/immune functions. Published data have shown that the endogenous 
production of H2S from rat aortic tissues is enhanced by NO donor treatment (Zhao et al., 
2001). The NO donor also enhances the expression level of CSE in cultured vascular 
SMCs. Hosoki et al. (Hosoki et al., 1997) observed that low concentrations of H2S 
(30µM) markedly enhanced the vasorelaxant effect of the NO donor sodium nitroprusside 
(SNP). On the contrary, pretreating aortic tissues with a higher dose of H2S (60µM) 
inhibited the vasorelaxant effect of SNP. Apparently, there is a complex crosstalk 
between H2S and NO, where direct action on synthases may be involved.  
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Non-vascular aspects of NO–H2S interactions have also been identified: it seems that 
NO-related effects contribute to the cytoprotective and antinociceptive effects of sulfide 
(Fiorucci et al., 2006). In macrophages, H2S inhibits the expression of iNOS but 
upregulates the expression of heme oxygenase-1 (Oh et al., 2006). H2S also acts as a 
scavenger and neutralizer of peroxynitrite (Whiteman et al., 2004), a key player in the 
cytotoxic effects of NO.  
CO may be another factor capable of interacting with H2S and NO. As noted above, 
H2S can also upregulate HO1, and can therefore induce a delayed production of CO. 
Given that all three bind avidly to hemoglobin, saturation of hemoglobin with one could 
lead to enhanced plasma levels and biological effects of the others (Wang, 1998). Indeed, 
saturation of erythrocytes with CO results in elevated plasma H2S levels (Searcy and Lee, 
1998). Additional studies are needed to examine the various interplays between the three 
gasotransmitters in health and disease, and to identify areas in which pharmacological 
modulation of these agents (alone or in combination) may provide therapeutic benefit 
(Szabó, 2007). 
1.5 Objectives and significance of the present study 
Studies have suggested that H2S plays a part in regulating heart contractility under 
physiological situation (Geng et al., 2004). However, the effect of H2S on the heart under 
pathological situation, such as ischemia, is still unknown. To date, most of the known 
effects of H2S are mediated through an action on KATP channels. Considering that 
opening of KATP channels is an essential event for development of ischemic 
preconditioning-induced cardioprotection and this protection could be mimicked by 
pharmacological opener of KATP channels, it merits study to investigate whether H2S 
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could exert a similar beneficial effect through opening KATP channels on a heart 
undergoing ischemic challenge.  
Therefore the objective of current study was to delineate the role of H2S in the 
cardioprotection against ischemia injury. To be specific, 1) endogenous H2S levels were 
assessed in both normal and ischemia-insulted myocardial tissues to examine whether 
endogenous H2S production altered during ischemia insult; 2) inhibitors of H2S 
biosynthesis were employed to investigate whether endogenous H2S contributed to the 
cardioprotection induced by ischemic preconditioning; 3) a sulfide donor was applied in 
an attempt to observe whether exogenous H2S could increase the resistance of myocardial 
tissues to ischemic attacks. Both in vitro and in vivo models were used to verify these 
issues at cellular level and the whole animal level. At the cellular level, isolated 
cardiomyocyte model was adopted due to its advantage in studying signaling mechanisms 
without confounding factors from the whole circulation. At whole animal level, a rat 
model of myocardial infarction was employed, as rats share considerable similarity on the 
cardiovascular system with humans.  
Accordingly, the findings from current study were expected to contribute to the 
knowledge in three areas: pathophysiology of cardiac ischemia, mechanisms of ischemic 
preconditioning-induced cardioprotection, and the biological profile of H2S. The results 
not only revealed a novel mechanism for ischemic preconditioning-induced 
cardioprotection, but also identified a simple and effective intervention approach for 
ischemic heart diseases. The results from in vivo experiments also provided valuable 
information for the translation from the bench to the bedside. 
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Chapter 2 Endogenous H2S mediates the cardioprotection induced 
by ischemic preconditioning in rat cardiomyocytes 
2.1 Introduction 
Hydrogen sulfide (H2S) represents the most recently identified endogenous gaseous 
messenger (Wang, 2002). The detection of plentiful H2S synthase CSE in the heart (Geng 
et al., 2004) suggests that endogenous H2S production is necessary for a well-functioned 
heart. However, it is not clear how the endogenous H2S level is associated with the 
heart’s condition. Thus we investigated whether there is a difference in endogenous H2S 
production between healthy cardiomyocytes and myocytes undergoing ischemia 
challenge.  
Ischemic preconditioning (IP) refers to the phenomenon that previous exposure to 
brief sublethal ischemia provides protection on the heart against subsequent severe 
ischemia insults (Murry et al., 1986). It is a powerful natural cardioprotective mechanism. 
A pivotal signaling event during IP is the opening of KATP channels (Sanada et al., 2004). 
The ability of H2S to open KATP channels in smooth muscle cells (Zhao et al., 2001) 
prompted us to investigate whether endogenous H2S also plays a part in the IP-induced 
cardioprotection. 
2.2 Materials and methods 
2.2.1 Isolation of adult rat cardiomyocytes 
Sprague-Dawely rats (190~210 g, male) were anesthetized with intraperitoneal (i.p.) 
injection of a combination of ketamine (75mg/kg) and xylazine (10mg/kg). Heparin 
(1000 IU) was administered i.p. to prevent coagulation during removal of the heart. The 
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heart was quickly excised, mounted on a Langendorff apparatus, and perfused in a 
retrograde fashion via the aorta with calcium-free Tyrode's solution (in mmol/L): 137 
NaCl, 5.4 KCl, 1 MgCl2, 10 HEPES, 10 Glucose, pH 7.4 at 37 °C. After 5 min the 
perfusion solution was changed to the Tyrode's solution containing 1 mg/ml collagenase 
type I and 0.28 mg/ml protease (type XIV) and perfused for a further 25-30 min. The 
perfusion solution was then changed to Ca2+-Tyrodes solution containing 2 × 10−4 mol/L 
CaCl2 without enzymes for an additional 5 min. The ventricular tissue was then cut into 
small pieces in a Petri dish containing pre-warmed Ca2+ Tyrode's solution and shaken 
gently to ensure adequate dispersion of dissociated cardiac myocytes. A 2.5 × 10−4 meter 
mesh screen was used to separate the isolated cardiac myocytes from cardiac tissue. The 
cells were then washed three times in Ca2+-Tyrode's solution and collected by 
centrifugation (500 rpm, for 1 min). Ca2+ concentration of the Tyrode's solution was 
increased gradually to 1.25 × 10−3 mol/L in 20 min. More than 80% of the cells were rod-
shaped and impermeable to trypan-blue. The cells were allowed to stabilize for 30 min 
before any experiments. 
2.2.2 Simulation of ischemia and ischemia preconditioning  
In the present study, we simulated ischemia with a pH 6.6 glucose-free Kreb’s buffer 
containing 10 mM 2-deoxy-D-glucose (2-DOG), an inhibitor of glycolysis (Macianskiene 
et al. 2001), and 10 mM sodium dithionite (Na2S2O4), an oxygen scavenger (Otter and 
Austin, 2000). This simulated ischemia solution produces a mixture of effects including 
metabolic inhibition, anoxia, and acidosis. When the solution was used for 
preconditioning purpose, the dose of 2-DOG and Na2S2O4 were halved to generate a 
milder ischemic condition.  
43 
 
2.2.3 Experimental protocol  
In the present study, we adopted two well-established preconditioning models to observe 
respectively the first and second phase of IP’s cardioprotection. For the induction of early 
phase of IP (Ho et al., 2002), cardiomyocytes were subjected to three cycle of brief 
ischemia and reperfusion, with each cycle composed of 3 min of preconditioning 
ischemia and 5 min of reperfusion with normal Dulbecco's modified Eagle's medium 
(DMEM) (shown in Fig 2-2A). Lethal ischemia was initiated subsequently and lasted for 
9 min, followed by reperfusion for 10 min. For the induction of late phase of IP (Nayeem 
et al., 1997; Wu et al., 1999), cells were subjected to a single episode of 30 min of 
preconditioning ischemia. Lethal ischemia was initiated 20 hours later and followed by 
10 min of reperfusion (shown in Fig. 2-4A). In each experiment, cells were divided into 
four groups: vehicle-treated group (VP), IP-treated group (IP), and either DL-
propargylglycine (PAG) or β-cyano-L-alanine (BCA) plus IP-treated groups (PAG+IP or 
BCA+IP). In the latter two groups, 2 × 10−3 mol/L PAG or 2 × 10−3 mol/L BCA were 
applied during IP. Cells in VP group were incubated with DMEM during preconditioning 
ischemia. 
2.2.4 Measurement of H2S concentration 
The culture media of cardiomyocytes were collected for measurement of endogenous H2S 
production. 75 µL media from each sample was added into an Ependorff tube that already 
contained 450 µL deionised water and 250 µL zinc acetate (1% w/v). Then N, N-
dimethyl-p-phenylenediamine sulphate (20 µM in 7.2 mol/L HCl, 133 µl) and FeCl3 
(30 µM in 1.2 mol/L HCl, 133 µL) were added in sequence for color development at 
room temperature. After 10 min, trichloroacetic acid (10% w/v, 250 µL) was added to 
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precipitate any protein that might be present in the media. The tubes were then 
centrifuged (10,000 × g) for 3 min and 300 µl aliquots from the resulting supernatants 
were transferred into a 96-well plate. Absorbance was determined at 670 nm using a 96 
well microplate reader (Tecan Systems Inc., U.S.A.). 
2.2.5 Assessment of cell viability and morphology 
Trypan blue exclusion was used as an index of myocyte viability (Zhou et al., 1996; 
Hiebert and Ping, 1997). After cells were incubated with 0.4% (w/v) trypan blue dye for 3 
min, living cells were unstained and termed nonblue cells. Nonblue cells/total cells were 
determined in a hemocytometer chamber using a light microscope (10x magnification). 
Cell morphology was also assessed by microscopic examination (Armstrong and Ganote, 
1994; Zhou et al., 1996). Percentage of rod-shaped (length/width ratio, >3:1) cells were 
determined as an indicator of the percentage of healthy cardiomyocytes. 200-500 cells in 
each of 5-7 cultures were tested for each group. 
2.2.6 Assessment of cellular injury 
Lactate dehydrogenase (LDH) release was used as an index of cellular injury (Nayeem et 
al., 1997). The activity in the cultured medium represents LDH release from the cultured 
ventricular myocytes. Both culture medium and cell lysates (prepared with lysis buffer 
containing 1% triton-X100) were collected for determination of LDH activity. LDH assay 
was performed using a commercially available kit (Sigma). The assay was based on the 
reduction of NAD catalyzed by LDH. The reduced NAD (NADH) was utilized in the 
stoichiometric conversion of a tetrazolium dye. The absorbance at a wave length of 
490nm was measured spectrophotometrically with a microplate reader (Tecon Systems 
Inc. U.S.A.). The background absorbance at 690nm was subtracted from the absorbance 
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at 490nm. The results were presented as LDH released into the medium in terms of 
percentage of the total LDH activity (medium + cell lysate) and normalized to 100% for 
VP group.   
2.2.7 Measurement of intracellular Ca2+ ([Ca2+]i) 
Ventricular myocytes were incubated with fura-2/AM (4 × 10−6 mol/L) (25 min) in 
Tyrode's solution supplemented with 1.25 × 10−3 mol/L CaCl2. The unincorporated dye 
was removed by washing the cells twice with fresh incubation solution. Loaded cells 
were kept at room temperature (24 °C-26 °C) for 30 min to allow the fura-2/AM in the 
cytosol to de-esterify. 
Loaded ventricular myocytes were then transferred to the stage of an inverted 
microscope (Nikon) in a superfusion chamber at room temperature. The inverted 
microscope was coupled with a dual-wavelength excitation spectrofluorometer 
(Intracellular imaging Inc, USA). Myocytes were perfused with Krebs' bicarbonate buffer 
(KB buffer, mmol/L; 117 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.25 CaCl2, 25 
NaHCO3, 11 glucose, with 1% w/v dialyzed BSA) and gassed with 95% O2/5% CO2. The 
myocytes selected for the study were rod-shaped with clear striations. These cells 
exhibited synchronous contraction (twitch) in response to suprathreshold (4 ms, 0.2 Hz) 
stimuli delivered by a stimulator (Grass S88) via two platinum field-stimulation 
electrodes immersed in the bathing fluid. Fluorescent signals obtained at 340 nm (F340) 
and at 380 nm (F380) excitation wavelengths were stored in a computer for data 
processing and analysis. The F340/F380 ratio was used to indicate [Ca2+]i level in the 
myocytes. 
2.2.8 Statistical Analysis.  
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Values presented are mean ± SEM. One-way ANOVA was used with a post hoc 
(Bonferroni) test to determine the difference between groups. The significance level was 
set at p < 0.05. 
2.2.9 Drugs and chemicals 
Type 1 collagenase, protease XIV, 2-DOG, PAG, BCA, N,N-dimethyl-p-
phenylenediamine sulfate, FeCl3, and trypan blue dye were purchased from Sigma-
Aldrich (St. Louis, MO). Fura-2 was purchased from Invitrogen (Carlsbad, CA). All 
chemicals were dissolved in distilled water except fura-2/AM, which was dissolved in 
DMSO at a final concentration < 0.1% (w/v) 
2.3 Results 
2.3.1Endogenous H2S production in rat cardiomyocytes was suppressed during 
ischemia and partly restored by IP 
To investigate whether endogenous H2S level is altered during ischemia, H2S 
concentration in cell culture medium after 9 min of ischemia was determined. The 
experimental procedures are shown in Fig. 2-1A and described under Materials and 
Methods. As shown in Fig. 2-1B, 9 min of ischemia significantly decreased endogenous 
H2S level to 23.7 ± 6.9% of that in VP group (n = 10, p < 0.001). Interestingly, 
preconditioning with three cycles of ischemia significantly attenuated the inhibitory effect 
of ischemia on H2S production (IP, 49.6 ± 9.5%, n = 5, p < 0.05 versus ischemia group). 
These data suggest that IP may protect the heart against ischemia at least partly by 










2.3.2 Early cardioprotection induced by IP was blocked by CSE inhibitors  
To determine whether endogenous H2S plays a part in the IP-induced early 
cardioprotection, PAG and BCA were used as inhibitors of endogenous H2S synthase and 
applied according to the protocol shown in Fig. 2-2A. We assessed the protective effects 
of 3 episodes of brief ischemia and reperfusion on cell viability and cell morphology in 
the presence and absence of CSE inhibitors. After 9 min of ischemia followed by 10min 
of reperfusion, the percentage of nonblue cells and percentage of rod-shaped cells in IP 
Figure 2-1 Effects of ischemia and IP on endogenous H2S production. (A) Experimental design. 
(B)Endogenous H2S production in normal rat cardiomyocytes (Con), cardiomyocytes undergoing 
ischemia (Ischemia), and cardiomyocytes subjected to IP (IP). Mean ± S.E.M.; n = 5 to 10. ***, p < 
0.001 versus Control; +, p < 0.05 versus ischemia. 
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group were significantly higher than those in vehicle-preconditioned (VP) group (Fig. 2-2 
B & C). The presence of 2 x 10-3 mol/L PAG or 2 x 10-3 mol/L BCA during IP reversed 
the cardioprotection on cell viability and morphology, while neither PAG nor BCA alone 
affected cell viability (control, 69.2 ± 3.2%; PAG, 63.4 ± 2.4%; BCA, 65.1 ± 1.7%, all n 








Figure 2-2 Effects of early IP on cell viability and cell morphology in the presence and absence of 
CSE inhibitors. (A) Experimental protocol. (B) Cell viability at 10 min into reperfusion in VP, IP, 
IP+PAG, and IP+BCA. (C) Percentage of rod-shaped cells at 10 min into reperfusion in VP, IP, 
IP+PAG, and IP+BCA. Mean ± S.E.M., n = 6 to 18 cultures of 500 cells each. **, p < 0.01 versus 




Electrical stimulation mimics the arrival of an action potential generated from the 
sino-atrial node of the heart, triggering the same cascade of events i.e.-membrane 
depolarization, influx of Ca2+, Ca2+ release from the SR and finally muscle contraction. 
We observed the recovery of electrically-induced [Ca2+]i transients (E[Ca2+]i) during 
ischemia and reperfusion to investigate whether inhibition of endogenous H2S formation 
would affect the cardioprotection of IP on cell function. As shown in Fig. 2-3A, the 
amplitude of E[Ca2+]i in VP group following ischemia and reperfusion was reduced to 
20.2 ± 3.8% of its initial amplitude. IP remarkably attenuated the wane of E[Ca2+]i during 
ischemia and reperfusion and [Ca2+]i transients in IP group was able to recover to 70.0 ± 
3.5% of its initial amplitude. Both PAG and BCA reversed this beneficial effect of IP 
(PAG, 34.8 ± 3.6%, n = 19; BCA, 37.8 ± 4.6%; n = 10, p < 0.001; Fig. 2-3B), while they 
did not produce significant effect on E[Ca2+]i when applied alone. These data suggest that 
endogenous H2S mediated the early phase of cardioprotection caused by IP on both cell 











Figure 2-3 Effects of early IP on recovery of electrically-induced [Ca2+]i transients (E[Ca2+]i) in 
the presence and absence of CSE inhibitors. Experimental procedures used were the same as those 
in Fig. 2-2A. (A) Representative tracings of E[Ca2+]i in VP and IP groups during ischemia and 
reperfusion. (B) Amplitude of E[Ca2+]i transients at 5 min of reperfusion. Mean ± S.E.M., n = 10 
to 26; ***, p < 0.001 versus VP; +++, p < 0.001 versus IP. 
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2.3.3 Late cardioprotection induced by IP was blocked by CSE inhibitors  
This series of experiments was designed to determine whether endogenous H2S is 
involved in the late phase of cardioprotection induced by IP. Experimental procedures 
were shown in Fig. 2-4A. Rat cardiomyocytes were subjected to I/R injury 20 hours after 
preconditioning ischemia. IP significantly increased the percentage of the non-blue cells 
per total number of cells at 10 min into reperfusion (31.8 ± 3.0%, n = 10, P < 0. 01) as 
compared with that found in VP group (20.8 ± 1.7%, n = 13). Pretreatment with PAG 
(2 × 10−3) mol/L or BCA (2 × 10−3 mol/L) blocked the cardioprotective effect of IP (Fig. 
2-4B).  
To further substantiate the role of endogenous H2S, we determined cellular injury 
using LDH release as an index. As shown in Fig. 2-4C, IP significantly decreased cellular 
injury caused by severe ischemia insults. Pretreatment with PAG or BCA blocked this 














Figure 2-4 Effects of late IP on cell viability and morphology in the presence and absence of 
CSE inhibitors. (A) Experimental protocol. (B) Cell viability at 10 min into reperfusion in VP, 
IP, IP+PAG, and IP+BCA. (C) Percentage of rod-shaped cells at 10 min into reperfusion in VP, 
IP, IP+PAG, and IP+BCA. Mean ± S.E.M., n = 6 to 18 cultures of 500 cells each. **, p < 0.01 
versus VP; +, p < 0.05 , ++, p < 0.01 versus IP. 
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The electrically-induced [Ca2+]i transients were also traced during reperfusion to 
examine the functional status of the cardiomyocytes. IP significantly improved the 
recovery of E[Ca2+]i which was compromised during ischemia (Fig. 2-5 VP & IP). Again, 
this beneficial effect was reversed by either of the H2S synthesis inhibitors, PAG 
(2 × 10−3 mol/L) or BCA (2 × 10−3 mol/L) (Fig. 2-5). Taken together, these data suggest 








2.3.4 CSE inhibitors reduced endogenous H2S level in rat cardiomyocytes  
This experiment was designed to confirm that the loss of IP cardioprotection observed in 
the presence of CSE inhibitors was indeed due to a decreased endogenous H2S level in 
the cell. As shown in Fig. 2-6, incubating cells with PAG or BCA at 2 x 10-3 mol/L for 40 
Figure 2-5 Effects of late IP on recovery of electrically-induced [Ca2+]i transients (E[Ca2+]i) in 
the presence and absence of CSE inhibitors. Experimental procedures used were the same as 
shown in Figure 2-4A. The amplitude of E[Ca2+]i in each group was determined at 5 min of 
reperfusion. Values are mean ± SEM; The number of myocytes sampled for calcium 
measurements were 9 (VP), 36 (IP), 38 (PAG+IP) and 42 (BCA+IP). ***P < 0.001 vs VP; 
+++P < 0.001 vs IP.  
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min, the conditions applied in the above experiments, significantly decreased H2S 





2.3.5 Sustained inhibition of endogenous H2S production caused cell injury.  
The above findings showed that inhibition of endogenous H2S disabled the 
cardioprotection caused by IP during ischemia. However, the consequence of sustained 
inhibition of endogenous H2S under physiological situation is unknown. Fig. 2-7 shows 
that incubation of the cardiac myocytes with PAG or BCA for 20 hours increased cellular 
injury index compared with the baseline level in normal cardiomyocytes. These data 
suggest that sustained inhibition of endogenous H2S causes cell injury and that 
endogenous H2S plays an important role in maintaining cell integrity during 
physiological situation. 
 
Figure 2-6 Effects of CSE inhibitors on endogenous H2S production. Mean ± S.E.M.; n = 5 to 10. 
***







The present study was primarily aimed to elucidate the role of endogenous H2S in IP-
induced cardioprotection. Since CSE is the main enzyme generating H2S in the heart 
(Zhao et al. 2001), CSE inhibitors were used. Of the inhibitors employed, PAG has been 
most studied. This compound causes an irreversible, mechanism-based inhibition of CSE 
enzyme activity in vitro (Johnston et al., 1979) and, when administered to rats, produces 
an almost complete inhibition of liver CSE enzyme activity (measured ex vivo) (Porter et 
al., 1996; Uren et al., 1978). Similarly, BCA has also been reported to cause potent and 
reversible inhibition of CSE activity (Uren et al., 1978; Pfeffer et al., 1967). In the 
present study, we examined the effects of PAG and BCA on the endogenous H2S 
production by measuring the concentration of H2S in the culture medium. Both drugs 
effectively reduced the H2S level in the culture medium, indirectly indicating a drop of 
intracellular H2S level. 
Figure 2-7 Effects of CSE inhibitors on cellular injury index. Cells were incubated with PAG and 
BCA for 20 hours. Mean ± SEM, N = 7-8. *P < 0.05 **P < 0.01 vs VP.  
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Based on the reliable effects of these tool drugs, the present study established an 
obligatory role of endogenous H2S in the cardioprotection afforded by IP. IP protects the 
cardiomyocytes against ischemia-induced cell death and injury as well as impairment on 
cell function. Inhibition of H2S biosynthesis with either PAG or BCA significantly 
diminished the protection observed in both the early and late phase of IP. Moreover, we 
also observed that H2S production was suppressed in cardiomyocytes subjected to 
ischemia. Preconditioning the cells with brief ischemia partly restored endogenous H2S 
level. Taken together, our data provide the first evidence that endogenous H2S is 
necessary for the development of both early and late cardioprotection of IP. 
It appears that endogenous H2S level determines the condition of the cardiomyocytes, 
since decreased H2S level is associated with ischemia and increased H2S level by IP is 
associated with cardioprotection. Indeed, we found that sustained inhibition of 
endogenous H2S production caused cell injury, suggesting that even under physiological 
situation, maintenance of certain endogenous H2S level is important for the wellness of 
the cardiomyocytes.  
Our results also demonstrated that IP was able to boost H2S production. Like the role 
of NO in the IP cardioprotection, the increased H2S in preconditioned cardiomyocytes is 
likely to contribute to the cardioprotection by activating some central components of the 
signaling pathway. Thus it is intriguing to observe whether direct preconditioning the 
cells with exogenous H2S is sufficient to induce cardioprotection without IP. 
In conclusion, the present study reveals a beneficial role of endogenous H2S in 
cardiomyocytes and provokes more interest to investigate the effect of exogenous H2S on 
the heart.   
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Chapter 3 H2S preconditioning induces biphasic cardioprotection 
against ischemic injury in rat cardiomyocytes 
3.1 Introduction 
We investigated in this series of experiments whether pretreatment with H2S before 
ischemia, namely, H2S preconditioning (SP), is able to attenuate ischemia-associated cell 
damages and its underlying mechanisms.  
3.2 Materials and methods 
3.2.1 Experimental protocol  
In the present study, H2S preconditioning was conducted following the same protocol 
used for induction of IP except for the replacement of IP buffer with Kreb’s buffer 
containing different concentrations of H2S. For the induction of early phase of SP, 
cardiomyocytes were subjected to three cycle of SP and reperfusion, with each cycle 
composed of 3 min of SP and 5 min of reperfusion with normal Dulbecco's modified 
Eagle's medium (DMEM). Lethal ischemia was initiated subsequently and lasted for 9 
min, followed by reperfusion for 10 min (shown in Fig 3-1A). For the induction of late 
phase of SP, cells were subjected to 30 min of SP. Lethal ischemia was initiated 20 hours 
later. To investigate the signal mechanisms for SP, cells in separated groups were treated 
respectively with non-selective KATP channel blocker glibenclamide (10−5 mol/L), 
sarcKATP blocker HMR-1098 (2 × 10−5 mol/L), mitoKATP bocker 5-HD (10−4 mol/L), NO 
synthase inhibitor L-NAME (10−4 mol/L), and PKC inhibitor chelerythrine (3 × 10−6 
mol/L) 15min before and during SP. Cells in VP group were incubated with DMEM 
during preconditioning ischemia. 
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3.2.2 Other methods 
Isolation of cardiomyocytes, simulation of ischemia, assessment of cell viability and 
morphology, intracellular Ca2+ imaging have been described in the Materials and 
Methods in Chapter 2.  
3.2.3 Statistical analysis 
Values presented are mean ± S.E.M. One-way analysis of variance was used with a post 
hoc (Bonferroni) test to determine the difference between groups. The significance level 
was set at p < 0.05. 
3.2.4 Drugs and chemicals 
L-NAME, 5-HD and chelerythrine chloride were purchased from Sigma Chemical Co, 
USA. HMR-1098 was a generous gift from Aventis Pharma Deutschland GmbH 
(Frankfurt, Germany). Glibenclamide was obtained from Tocris Cookson Ltd, UK. All 
chemicals were dissolved in deionized water except glibenclamide, which was dissolved 










3.3.1 SP induced immediate cardioprotection in rat cardiomyocytes  
Cell viability and morphology were assessed in both H2S-preconditioned cells (SP) and 
vehicle-preconditioned cells (VP) 10 min into reperfusion after lethal ischemia (Fig. 3-
1A). As shown in Fig. 3-1B, three cycles of 5 min of exposure to different concentrations 
of NaHS (10-6, 10-5, 10-4, and 10-3 mol/L) increased the percentage of nonblue cells in a 
concentration-dependent manner. Cell viability in SP was significantly higher than that in 
VP group when NaHS concentration reaches 10-5 mol/L, and the maximum protective 
response was observed at 10-4 mol/L of NaHS (VP, 32.6 ± 2.1%; 10-5 mol/L NaHS, 45.9 
± 2.3%; 10-4 mol/L NaHS, 47.9 ± 2.2%; all n = 7; Fig. 3-1B). 
 To compare the responses in term of morphology change, the percentage of rod-
shaped cells was determined. As shown in Fig. 3-1C, pretreatment with NaHS at 10-5 
mol/L and 10-4 mol/L preserved a greater percentage of rod-shaped cells than VP group 
(VP, 28.9 ± 3.3%; 10-5 mol/L NaHS, 41.3 ± 2.8%; 10-4 mol/L NaHS, 43.4 ± 3.1%; all n = 
7). These data indicate that H2S preconditioning is able to produce an IP-like effect on 















Figure 3-1 Early cardioprotection induced by SP in rat cardiomyocytes. (A) Experimental design. 
Solid fields, simulated ischemia; open fields, DMEM; slashed fields, DMEM containing different 
concentrations of NaHS. (B) Concentration-dependent effect of SP on cell viability. Nonblue cells 
were living cells. Mean ± S.E.M.; n = 7 cultures of 500 cells each. ++, p < 0.01; +++, p < 0.001 versus 
VP. (C) Concentration-dependent effect of SP on cell morphology. Rod-shaped cells per total cells 
were counted. Mean ± S.E.M.; n = 7 cultures of 500 cells each. +, p < 0.05; ++, p < 0.01 versus VP.  
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To determine the functional status of the cells, electrically induced [Ca2+]i transients 
(E[Ca2+]i) before, during, and after ischemia were recorded. As shown in Fig. 3-2, the 
amplitude of E[Ca2+]i in VP group was decreased by ischemia and reperfusion to 25.8 ± 
3.0% of the amplitude of normal E[Ca2+]i transients in control group. Preconditioning 
cells with H2S significantly attenuated this effect, suggesting that SP improved the cell 





Figure 3-2 Effect of SP on recovery of electrically induced [Ca2+]i transients (E[Ca2+]i) in single 
cardiomyocytes. (A) Representative tracings of E[Ca2+]i in VP and SP groups. (B) Group results 
showing the amplitudes of E[Ca2+]i in normal myocytes (Con) and myocytes in VP and SP groups at 
10 min into reperfusion. Values are mean ± S.E.M.; n = 25. ***, p < 0.001 versus the value in the Con 
group; +++, p < 0.001 versus the value in the VP group.  
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3.3.2 SP induced late cardioprotection in rat cardiomyocytes 
To investigate whether H2S was able to produce late cardioprotection against ischemic 
injury, cardiomyocytes were subjected to lethal ischemia 20 hours after they were 
preconditioned with different concentrations of H2S (Fig. 3-3A). After 5 min of severe 
ischemia and 10 min of reperfusion, the percentage of non-blue cells was 21.4 ± 7.0% 
(N = 15) in VP group (Fig. 3-3B). In SP groups where cells were pretreated with 
10−6~10−3 mol/L NaHS for 30 min, the percentage of non-blue cells was significantly 
higher than that of VP group when the NaHS concentration was 10−5 mol/L and the 
maximum protective response was observed at a concentration of 10−4 mol/L 
(38.5 ± 4.9%, N = 9).  
A similar result was found when using the percentage of rod-shaped cells as an 
indicator of the cell conditions. Only 10.8 ± 1.7% (N = 10) of the cells were rod-shaped 
in VP group. NaHS at 10−5 ~ 10−4 mol/L significantly increased the percentage of rod-
shaped cells. The maximum protection reached at 10−4 mol/L NaHS (16.4 ± 2.0%, N = 11; 
Fig. 3-3C). These dose-dependent responses are consistent with those found in the early 
phase of SP-induced cardioprotection, indicating that SP is able to induce biphasic 













Figure 3-3 Late cardioprotection induced by SP in rat cardiomyocytes. (A) Experimental protocol. 
Ischemia was induced 20 hours after preconditioning. (B) Concentration-dependent effect of NaHS on 
cell viability. Values are presented as non-blue cells per total myocytes counted. (C) Concentration-
dependent effect of NaHS on cell morphology. Values are presented as rod-shaped cells per total 
myocytes counted. All data are mean ± SEM; N = 5-15 cultures of 200-500 cells each. *P < 0.05, 
***P < 0.001 vs VP.  
64 
 
3.3.3 SP-induced late cardioprotection lasted at least 28h 
Because of the clinical significance of the late cardioprotection, we investigated the time 
course of the protective effects by determining cell viability and morphology at different 
time points (1, 6, 16, 20, and 28 hours) after 30 min of exposure to H2S (Fig. 3-4A). 
Despite decreased viability with increased culture period, SP groups at 1, 16, 20 and 
28 hours still displayed higher percentage of nonblue cells compared with time-matched 
VP groups (Fig. 3-4B). Similar results were also found when examining cell morphology 
(Fig. 3-4C). These data confirmed that there are two windows of cardioprotection 
induced by H2S preconditioning and also further demonstrated that SP-induced late 








Figure 3-4 Time course of SP-induced cardioprotection. (A) Experimental protocol. After pretreatment, 
cells were cultured in DMEM for 1, 6, 16, 20, and 28 hours respectively before being subjected to severe 
ischemia (IS) for 5 min followed by 10min of reperfusion (RE). Cell viability (B) and cell morphology 
(C) were examined at 10 min into reperfusion. Values are presented as mean ± SEM; N = 5-16 cultures 




3.3.4 SP-induced late cardioprotection counteracts different periods of ischemia and 
reperfusion  
These series of experiments were designed to determine the effectiveness of SP-induced 
late cardioprotection against different periods of ischemia and reperfusion. As shown in 
Fig. 3-5B&C, after 5 min, 10 min or 30 min of ischemia and 10 min of reperfusion, cell 
viability and percentage of rod-shaped cells in SP groups were significantly higher than 
those in corresponding VP groups.  
We also observed the cardioprotective effects of SP at different time points during 
reperfusion. SP increased myocyte viability and percentage of rod-shaped cells at 10 min, 
20 min or 60 min into reperfusion (Fig. 3-6). These data suggest that SP protects 
cardiomyocytes from different periods of ischemic insults and the cardioprotection lasts 











Figure 3-5 Late cardioprotection induced by SP against different periods of ischemia. (A) 
Experimental protocol. Cells were subjected to different periods of ischemia (IS) after 20 hours 
culture. Cell viability (B) and cell morphology (C) were examined at 10 min into reperfusion (RE). 
Values are presented as mean ± SEM; N = 5-16 cultures of 200~600 cells each. *P < 0.05, 










Figure 3-6 Late cardioprotection induced by SP against different periods of reperfusion. (A) 
Experimental protocol. After 20 hours of culture, cardiomyocytes were subjected to 5 min of ischemia 
(IS) followed by different periods of reperfusion (RE). Cell viability (B) and cell morphology (C) 
were examined at 10 min, 20 min or 1 hour into reperfusion (RE). Values are presented as 
mean ± SEM; N = 5-16 cultures of 200~600 cells each. *P < 0.05, **P < 0.01, ***P < 0.001 vs 
corresponding VP groups.  
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3.3.5 SP-induced late cardioprotection was blocked by KATP inhibitors 
The goal of this series of experiments was to probe the mechanism(s) involved in the late 
cardioprotection of SP. The experimental procedures were shown in Fig. 3-7A. Treatment 
with glibenclamide (10−5 mol/L), a non-selective KATP blocker, 15 min before and during 
SP significantly attenuated the cardioprotection observed in SP groups, as manifested by 
the reduced cell viability and increased cellular injury (LDH release) compared with SP 
groups (Fig. 3-7B&C). The contribution of each subtype of KATP channels was also 
assessed by using subtype-specific blockers, 5-HD (10−4 mol/L, a mitochondrial KATP 
blocker), and HMR-1098 (2 × 10−5 mol/L, a sarcolemmal KATP blocker). As shown in Fig. 
3-7B&C, HMR-1098 but not 5-HD reversed SP-induced protective effects on cell 
viability and injury, suggesting that only sarcolemmal KATP plays a part in the 
cardioprotection of SP. In separate experiments, glibenclamide, 5-HD or HMR-1098 


















Figure 3-7 Effects of SP on cell viability and cellular injury in the presence and absence of KATP channel 
blockers. (A) Experimental design. Glibenclamide (Gliben), 5-HD and HMR-1098 (HMR) were applied 
15 min before and during SP. (B) Cell viability. Values were presented as non-blue cells per total 
myocytes counted; n=6-7 cultures of ≈200-500 cells each. (C) Cellular injury index. Values were 
presented as supernatant LDH activity/total LDH activities (supernatant + cells lysate). N = 5. 
Mean ± SEM. * P < 0.05, **P < 0.01 vs VP; +P < 0.05, ++P < 0.01, +++P < 0.001, vs SP.  
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To determine whether KATP channels are also involved in the protection of SP on cell 
function, we observed the electrically-induced [Ca2+]i transients during ischemia and 
reperfusion in myocytes co-pretreated with H2S and KATP blockers. Fig. 3-8 shows that 
the protective effect of SP was significantly attenuated by glibenclamide and HMR-1098, 













Figure 3-8 Effects of SP on recovery of E[Ca2+]i amplitude in the presence and absence of KATP 
channel blockers. The amplitude of E[Ca2+]i was determined at 10 min into reperfusion. Values are 
mean ± SEM; The numbers of myocytes sampled for measurements were 22 (VP), 20 (SP), 38 
(Gliben + SP), 16 (5-HD + SP) and 12(HMR + SP). ***P < 0.001 vs VP; +++P < 0.001 vs SP.  
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3.3.6 SP-induced late cardioprotection was blocked by a NO synthase inhibitor 
To examine the involvement of NO in the cardioprotection of SP, L-NAME (10-4 mol/L) 
was used as a non-selective inhibitor of all NO synthase. L-NAME significantly 
attenuated the cardioprotection of SP on cell viability (shown in Fig. 3-9A) and cell 








Figure 3-9 Effects of SP on cell viability and E[Ca2+]i transients in the presence and absence of a NO 
synthase inhibitor, L-NAME. (A) Experiment protocol. (B) Cell viability at 10 min into reperfusion. 
Mean ± SEM; N = 6-7 cultures of ≈200-500 cells each. (C) Amplitude of E[Ca2+]i transients at 10 
min into reperfusion. The number of myocytes sampled for calcium measurements were 22 (VP), 39 
(SP) and 46 (L-NAME+SP). ***P < 0.001 vs VP; +P < 0.05, +++P < 0.001 vs SP. 
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3.3.7 SP-induced late cardioprotection was blocked by PKC inhibitors 
To determine the role of PKC in the SP-induced cardioprotection, PKC inhibitors, 
chelerythrine (3 x 10-6 mol/L, chelery) and calphostine C (10-7 mol/L, Cal C) were 
applied 15 min before and during SP preconditioning (Fig. 3-10A). Both drugs, which 
alone had no effects, blunted the cardioprotection of SP on cell viability and cellular 






Figure 3-10 Effects of SP on cell viability and cellular injury in the presence and absence of PKC 
inhibitors. (A) Experiment protocol. Chelerythrine (Chelery) and Calphostine C (Cal C) were apllied 
15 min before and during SP. (B) Cell viability. Values were presented as non-blue cells per total 
myocytes counted. n=5-13 cultures of ≈200-500 cells each.  **P<0.01 vs VP; +P<0.05 vs SP. (B) 
Cellular injury index. Values were presented as supernatant LDH activity/total LDH activities 
(supernatant + cell lysate) normalized to 100% of VP group (control).  n=6. Mean ± SEM; **P<0.01 vs 




In the present study, we investigated the effect of exogenous H2S on rat cardiomyocytes 
undergoing lethal ischemia. We found that NaHS, a donor of H2S, produced biphasic 
cardioprotection against ischemia-caused damages. The first phase of cardioprotection 
occurred immediately after H2S preconditioning, while the second phase is observable 
between 16 hours and 28 hours after H2S preconditioning. Due to the limited time that 
cardiomyocytes can survive in vitro, it is technically difficult to observe the late phase of 
cardioprotection after 28 hours. However, it is very likely that the late cardioprotection 
could last much longer, as the protective effect was still very strong at 28 hours. These 
data suggest that SP follows a similar time course as IP, which also produces immediate 
(1 to 2 hours) and delayed (12 to 72 hours) protection against ischemia (Murry et al., 
1986; Kuzuya et al., 1993; Marber et al., 1993).  
In both phases, NaHS at 10−5-10−4 mol/L concentration-dependently increased the cell 
viability and the percentage of rod-shaped cells. The maximum protective effect was 
always observed at 10−4 mol/L NaHS. Accordingly, we used the concentration 10−4 
mol/L for all subsequent in vitro experiments. 
Considering the greater clinical importance of the late cardioprotection, we performed 
detailed study on its effectiveness against I/R injury in varied experimental settings. We 
found that H2S preconditioning protected cardiomyocytes against different periods of 
ischemia. As the duration of ischemia increases, the protection appears more significant 
on cell morphology than on cell viability, which implies that SP-induced cardioprotection 
is particularly effective in salvaging more percentage of functional cells rather than living 
cells.  Similar results were also found when cell viability and cell morphology were 
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determined after different periods of reperfusion. The pronounced protection observed in 
SP group after 60 min of reperfusion indicates that the effect of H2S preconditioning is 
prevention instead of delay of cell death. 
In an attempt to probe the signaling mechanism underlying the late cardioprotection, 
we determined the involvement of KATP channels, NO and PKC due to their important 
roles in the late cardioprotection of IP. There are two separate populations of KATP 
channels within the myocardium: the sarcKATP and mitoKATP channels (Gross and Fryer, 
1999). Both sarcKATP channels and mitoKATP channels have been reported to trigger or 
mediate the cardioprotective effects of IP (Gross and Peart, 2003). Initial evidence 
suggested that the sarcKATP channels triggered or mediated the cardioprotective effects of 
IP (Jovanovic et al., 1986; Toyoda et al., 2000); however, more recent findings have 
suggested a major role for mitoKATP channels (Gross and Peart, 2003; Liu et al., 1998; 
Liu et al., 1999). In this study, we found that both non-selective KATP channel blocker 
glibenclamide and selective sarcKATP blocker HMR-1098 reversed the cardioprotection 
of SP, while selective mitoKATP blocker 5-HD failed to affect the protection of SP. These 
data clearly indicate that sarcKATP is the subtype of KATP channel that mediates the SP-
induced late cardioprotection. Opening of sarcKATP channels is associated with potassium 
efflux, depolarization of cell membrane and shortening of APD (Noma, 1983; Cole et al., 
1981). These effects reduce Ca2+ influx via L-type Ca2+ channels and prevent the reversal 
of the Na+-Ca2+ exchange system. The resultant decrease in Ca2+ influx would be 
expected to lead to a reduction of the mechanical contraction, blunting of intracellular 
Ca2+ overload, and energy sparing during ischemia and early reperfusion. 
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The present study also demonstrated an essential role of PKC in SP-induced late 
cardioprotection with two different PKC inhibitors. The involvement of PKC is probably 
secondary to the opening of KATP channels, since H2S has been shown to directly open 
KATP channels in smooth muscle cells (Zhao et al., 2001).  However, activation of PKC 
and KATP channel could also be codependent (Baxter et al., 1995; Gross and Peart, 2003), 
given that protection provided by direct KATP channel openers could be abolished by 
PKC antagonists and vice versa (Gaudette et al., 2000). Additional experiments are 
needed to determine whether opening of KATP channels is an event upstream of PKC 
activation in SP-induced late cardioprotection. In addition, the two PKC inhibitors used, 
chelerythrine and calphostin C, are not isoform-selective, which warrants further studies 
to determine the specific isoforms involved.  
The role of NO in the SP-induced cardioprotection is another focus of interest in this 
study. Over the past decade, many studies have revealed a critical role of NO in IP-
induced cardioprotection (Bolli, 2001). Importantly, NO alone is also sufficient to induce 
late cardioprotection against myocardial ischemia (Takano et al., 1998). In the present 
study, we found that inhibition of NO synthesis with L-NAME significantly attenuated 
the cardioprotection of H2S on both cell viability and cell function. This is another line of 
evidence supporting the concept that crosstalk exits between endogenous 
gasotransimitters (Szabó, 2007).  
In conclusion, the present study has demonstrated, for the first time, that 
pharmacological preconditioning with the H2S donor NaHS is able to confer 
cardioprotection against ischemia probably via activation of sarcKATP channel, PKC and 
release of NO. 
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Chapter 4 H2S preconditioning-induced PKC activation regulates 
intracellular calcium handling in rat cardiomyocytes 
4.1 Introduction 
The study in Chapter 3 has revealed that PKC is involved in the SP-induced 
cardioprotection.  The PKC family consists of at least 10 isoforms, of which PKC-α, ε, 
and δ are the prominent isoforms expressed in the heart (Mackay and Mochly-Rosen, 
2001). Upon stimuli, PKC isoforms translocate from the cytosol to subcellular membrane 
regions, a process associated with their activation (Mackay and Mochly-Rosen, 2001). 
However, it is completely unknown which isoforms could be activated by H2S 
preconditioning and how they mediate or execute the cardioprotection. 
PKC activation has been reported to play a role in regulating intracellular calcium 
handling (Ladilov et al., 1998; Stamm et al., 2001; Stamm and del Nido, 2004). Under 
the physiological condition, intracellular calcium concentration is sophisticatedly 
regulated by several proteins present in the sarcolemmal and sarcoplasmic reticulum (SR) 
membranes. Upon the arrival of action potential, Ca2+ influxes through the L-type Ca2+ 
channel and triggers the opening of the ryanodine receptor (RyR), resulting in further 
release of Ca2+ from SR, which accomplishes the sharp [Ca2+]i elevation required for 
myofibril contraction (Guatimosim et al., 2002). In the rat cardiomyocytes, >90% of the 
Ca2+ after contraction is immediately uptaken by SR via sarco(endo)plasmic reticulum 
Ca2+-ATPase (SERCA), while the remaining Ca2+ is pumped out of the cell via Na+/Ca2+ 
exchanger (NCX) (Bers, 2000).  
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However, the well-controlled intracellular Ca2+ homeostasis could be easily disrupted 
by ischemia and reperfusion insults. During ischemia, excessive Ca2+ accumulates in the 
cytosol (Piper et al., 1993) and leads to a series of severe damages upon reperfusion. For 
example, once re-energized by reperfusion, cardiac myofilaments contract in an extreme 
and sustained manner (hypercontracture) due to overstimulation of calcium on the 
contractile apparatus (Siegmund, 1993). In single cardiomyocytes, such hypercontracture 
causes irreversible shortening of cell length. In tissues, it causes a disruptive change in 
myocardium termed contraction band necrosis (Ganote, 1983).  Under this circumstance, 
a faster clearing of excessive Ca2+ from cytosol is therapeutically important as it would 
potentially attenuate Ca2+ overloading during ischemia (Abdallah et al., 2005) and 
prevent subsequent damages. Since PKC is implicated in the intracellular Ca2+ handling, 
it is worthwhile investigating whether H2S could alter intracellular Ca2+ handling via 
activation of PKC. 
 Taken together, there is no information so far available regarding the isoforms of 
PKC involved in H2S preconditioning and how the cardioprotective signals are conveyed 
forwards.  Thus in the current chapter, a close inspection on PKC was performed with an 
emphasis on its upstream and downstream connections in the signal transduction pathway 
of H2S preconditioning.  
4.2 Materials and Methods 
4.2.1Experimental protocol 
Myocytes were subjected to H2S preconditioning (SP) by incubation with 10-4 mol/L 
NaHS for 30 min.  20 hours later, samples were harvested for western blotting 
experiment or for intracellular Ca2+ transient recording. To study the sequence of 
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signaling events between PKC activation and KATP opening, cells were treated with 
glibenclamide (10-5 mol/L, a blocker of KATP channel) 15 min before and during SP. In 
separate experiments, preconditioned cells were subjected to severe ischemia followed by 
10min’s reperfusion with normal medium. Resting Ca2+ was traced real-time during 
ischemia for examination on cytosolic Ca2+ accumulation. Cell lengths before ischemia 
and after the onset of reperfusion were compared for evaluation of hypercontracture.  
4.2.2 Cell fractionation and western blotting 
A cell fractionation technique was adopted from the literature (Mackay and Mochly-
Rosen, 2001; Weber et al., 2005). After 20h’s incubation, cardiomyocytes were lysed 
with 150 µl ice-cold lysis buffer containing 125mM NaCl, 25mM Tris pH7.5, 5mM 
EDTA, 1% NP-40 and protease inhibitors and shaken on ice for 1h. The cell lysate was 
centrifuged at 1000×g at 4oC for 10 min for rough partition between cytosolic and 
membrane fractions. The supernatant was recentrifuged at 16000×g at 4oC for 15min to 
get rid of contaminating pellet materials and collected as cytosolic fraction. The initial 
pellets were resuspended in 100 µl cell lysis buffer containing 1% triton X-100 and 
shaken on ice for another 60min and were then centrifuged at 16000×g at 4oc for 15min. 
The second supernatant was collected as membrane fraction. Epitopes were exposed by 
boiling the protein samples at 90oc water for 5 min. Each fraction was analyzed for 
protein content by Bradford assay. Equal amounts of protein were loaded and 
electrophoresed with 10% SDS-polyacrylamide gel and transferred to a polyvinylidene 
difluoride membrane (Amersham Biosciences, U.K.). The membrane was probed with 
antibody against PKCε (Santa Cruz Biotechnology, Inc., California, U.S.A.), PKCα and 
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PKCδ (Cell Signaling Technology, Inc., Danvers, U.S.A). Immunoreactivity was 
detected using an ECL advance western blot detection kit (Amersham Biosciences, U.K.). 
4.2.3 Measurement of [Ca2+]i 
Electrically induced [Ca2+]i transients (E[Ca2+]i) were generated by stimulating myocytes 
with a stimulator at 0.2 Hz (Grass S88). Caffeine-induced [Ca2+]i transients (C[Ca2+]i) 
were generated by adding 10-2 mol/L caffeine directly to the incubation buffer. Resting 
Ca2+ level was recorded during ischemia challenge without any electrical or caffeine 
stimulations.  
4.2.4 Measurement of cell length 
Cardiomyocytes were placed on the stage of an inverted microscope (Nikon TE2000-S). 
The cell image was taken with a digital camera (Nikon DS-5M-L1) connected to the 
microscope with a 20X objective and analyzed with NIS-documentation software (Nikon).  
4.2.5 Statistical analysis 
Values presented are mean ± SEM. Statistic comparisons were performed by one-way 
ANOVA and bonferroni for post-hoc analysis. The significance level was set at P<0.05. 
4.3 Results 
4.3.1 SP promoted translocation of PKC α,ε and δ to membrane fraction 
To determine the activated PKC isoforms in the delayed phase of cardioprotection 
induced by SP and IP, subcellular distributions of three main PKC isoforms present in the 
heart, α, ε and δ, were examined with western blotting experiments 20h after SP and IP. 
As shown in Fig. 4-1, SP induced all three isoforms of PKC translocation from cytosol to 
81 
 
membrane. The membrane/cytosol ratios of PKC-α,ε and δ abundance increased 
approximately two folds in SP group compared with VP group (Fig. 4-1D-F). 
Interestingly, IP only induced translocation of PKCε and δ, but had no effect on PKCα 
translocation. These data suggest that the SP and IP may employ different subsets of PKC 





Figure 4-1. Effects of IP and SP on subcellular distribution of PKCα (A&D), PKCε (B&E), and 
PKCδ (C&F). (A-C) Representatives of five separate experiments for each isoform. (D-F) Gourp 
results of membrane/cytosol ratio of PKC isoform abundance. They are calculated by relative 
densitometry and normalized to 100% of VP group. The data are presented as mean ± SEM, n=5, 
*P<0.05 **P<0.01 vs VP. 
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4.3.2 KATP channel blocker prevented translocation of PKCε  
Glibenclamide (10-5 mol/L), a KATP channel blocker, was used to examine whether SP-
induced translocation of PKC isoforms was secondary to the opening of KATP channels. 
As shown in Fig. 4-2, glibenclamide blocked SP-induced translocation of PKCε but did 
not affect translocation of PKCα and PKCδ, suggesting that only PKCε among the three 




Figure 4-2. Effects of KATP blockers on SP-induced translocation of PKC isoforms. Glibenclamide was 
applied 10 min before and during SP treatment. (A-C) Representatives of five separate experiments for 
each isoform. (D-F) Correspondent membrane/cytosol ratios calculated by relative densitometry and 
normalized to 100% of VP group. The data are presented as mean ± SEM, n=5~7, *P<0.05 **P<0.01 
vs VP, ++P<0.01 vs SP. 
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4.3.3 SP accelerated SR-Ca2+ uptake rate in a PKC-dependent manner  
The decline rate of [Ca2+]i is mainly determined by Ca2+ uptake to SR via SERCA, which 
is responsible for the removal of ~90% Ca2+ from the cytosol (Bers, 2000). Thus t50 (half-
decay time) and t90 (90% decay time) of E[Ca2+]i were measured as indicators of SR 
uptake rate. As shown in Figure 4-3, both t50 and t90 were significantly shortened in SP 
group, compared with those observed in VP. Co-treatment with 3 x 10-6 mol/L 
chelerythrine during SP reversed this effect, suggesting that SP accelerated the rate of 




Figure 4-3. Effects of SP on SR-Ca2+ uptake rate in single ventricular myocytes in the presence and 
absence of PKC inhibitor. (A) Typical transients of E[Ca2+]i in VP, SP and SP+Chelerythrine 
(SP+Che). Half-decay time t50 (B) and 90% decay time t90 (C) of E[Ca2+]i indicate the rate of Ca2+ 
uptake to SR via SERCA. The data are presented as mean ± SEM, n=14(VP), 11(SP), 7(Che). *P<0.05 
vs VP, **P<0.01 vs VP, +P<0.05 vs SP. ++P<0.01 vs SP. 
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4.3.4 SP accelerated Ca2+ extrusion rate in a PKC-dependent manner  
Because caffeine keeps RyR open, SR is unable to sequester Ca2+ during its application. 
The decline of [Ca2+]i therefore depends on Ca2+ extrusion through NCX (Sham et al., 
1995).  The rate of extrusion can be reflected by decay of C[Ca2+]i  (t50 and t90). As shown 
in Figure 4-4, SP significantly shortened both t50 and t90 of the decay of C[Ca2+]i. These 
effects were reversed by inhibition of PKC with chelerythrine (3 x 10-6 mol/L). We also 
examined the SR-Ca2+ load by measuring the amplitude of C[Ca2+]i  since caffeine 
depletes the intracellular Ca2+ store at a burst. The amplitude did not differ between 


















4.3.5 SP attenuated cytosolic Ca2+ accumulation during ischemia in a PKC-
dependent manner 
Resting Ca2+ elevation was traced during ischemia to investigate whether the Ca2+ 
handling altered by SP affected the Ca2+ accumulation in the cytoplasm during ischemia 
challenge. As shown in Fig. 4-5, the resting Ca2+ level in VP increased dramatically 
within 15 min of ischemia, indicating a severe Ca2+ accumulation in the cytosol. 
Figure 4-4. Effects of SP on Ca2+ extrusion rate in single ventricular myocytes in the presence and 
absence of PKC inhibitor. (A) Typical transients of C[Ca2+]i  in VP, SP and SP+Chelerythrine (SP+Che) 
Half-decay time t50 (B) and 90% decay time t90 (C) of C[Ca2+]i  indicate the rate of Ca2+ extrusion via 
NCX. Amplitude (D) of C[Ca2+]i  reflects the Ca2+ load in SR. The data are presented as mean ± SEM, 
n=13(VP), 9(IP), 13(SP), 8(Che), 12(Gliben). *P<0.05 vs VP, **P<0.01 vs VP, **P<0.001 vs VP,  
++P<0.01 vs SP. 
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However, the increase of resting Ca2+ in SP was limited to a much lower extent.  







4.3.6 SP attenuated myocyte hypercontracture at the onset of reperfusion in a PKC-
dependent manner  
Figure 4-5. Effects of SP on cytosolic Ca2+ accumulation during ischemia in the presence and absence 
of PKC inhibitor. (A) Typical tracings of resting Ca2+ level during 15 min of ischemia challenge in 
single cardiomyocytes in VP, SP and SP+Chelerythrine (SP+Che). (B) Group results. Data are 
presented as the area under the Ca2+ increase curve within 10 min of ischemia and normalized to 100% 
of control. Values are mean ± SEM, n=6, **P<0.01 vs VP, ++P<0.01 vs SP. 
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Hypercontracture refers to the sustained maximum contractile activation of myofibrils 
resulting from the combination of excessive cytosolic Ca2+ accumulation during ischemia 
and energy resupply after reperfusion (Siegmund et al., 1993). We determined cell length 
shortening few minutes after the onset of reperfusion in an attempt to investigate whether 
SP may also alleviate hypercontracture. As shown in Fig. 4-6, in VP group myocyte 
length was shortened to about half of their initial length after reperfusion. SP significantly 
attenuated this detrimental shortening and this effect was abolished by inhibition of PKC 





In the current study we found that SP-induced PKC isoform activation accelerates the 
rectification of elevated [Ca2+]i and thereby increases the susceptibility of cardiomyocytes 
Figure 4-6. Effects of SP on myocyte hypercontracture at the onset of reperfusion. Mean data 
showing the cell lengths before ischemia and after onset of reperfusion in VP, SP and 
SP+Chelerythrine (SP+Che). Mean ± SEM, n=30~50, **P<0.01 vs VP, ++P<0.01 vs SP. 
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to ischemia-induced Ca2+ overload and consequent damages induced by reperfusion. 
These findings disclose a novel mechanism for SP-induced cardioprotection and also 
provide considerable implication for other PKC-related anti-ischemia interventions. 
4.4.1 PKC isoform translocation  
Although PKC activation seems to be coupled with the genesis of late phase of 
cardioprotection induced by SP, the specific PKC isoforms involved is still unknown. 
PKC-α, ε, δ are the three main isoforms expressed in adult cardiomyocytes and also the 
most important ones involved in cardioprotection of ischemic preconditioning (Rybin and 
Steinberg, 1994; Kawamura et al., 1998). For this reason, we examined the effect of SP 
on these three isoforms before ischemia insults which itself can stimulate PKC 
translocation. We found that H2S preconditioning motivated translocation of the three 
isoforms PKC-α, ε and δ to membrane fraction at 20h after preconditioning. Such 
translocation prior to ischemia attack may act as an essential step to switch the cells into a 
state tolerant to ischemia insults, and failure of such translocation results in the loss of 
cardioprotection as observed in the presence of a PKC inhibitor.  
Individual PKC isozymes are believed to mediate characteristic cell functions, as 
upon stimuli they are directed to distinct subcellular membrane regions by isozyme-
specific receptors for activated C kinase (RACK) (Mackay and Mochly-Rosen, 2001). By 
binding to their specific RACKs the activated isozymes are anchored close to their 
particular substrates. In the present study, we employed IP as a reference model due to its 
recognized stimulatory effect on PKC. Intriguingly, we found that IP only promoted 
PKCε and PKCδ translocation but not that of PKCα. The discrepancy between SP and IP 
suggests that they may employ different subsets of PKC isoforms to convey their 
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cardioprotective signals to different subcellular regions, affording probably similar but 
not identical cardioprotection.  
4.4.2 PKC and KATP  
Since H2S has been shown to have a direct effect on KATP channels (Zhao et al., 2001; 
Tang et al., 2005), it raises the question whether SP-induced PKC activation is secondary 
to the opening of KATP channels. Unexpectedly, we observed that blockade of KATP 
channel only diminished the SP-induced translocation of PKCε but failed to affect the 
translocation of PKCα and δ. Thus, KATP channel opening may only be necessary for 
PKCε activation in the SP signaling pathway.  
It is until recently that individual PKC isoforms were found located differently in 
relation to KATP channels in the cardioprotective signaling pathway. Hassouna 
demonstrated that PKCε is located upstream whereas PKCα is downstream to mitoKATP 
channel in IP signaling pathway (Hassouna et al., 2004). This implies a considerable 
diversity of the signaling mechanisms whereby PKC isoforms are activated. Since PKC 
can also be activated by other signaling molecules like NO or Ca2+ (Miyawaki and Ashraf, 
1997; Ping et al., 1999), more studies are warranted to test whether SP induces activation 
of PKCα and PKCδ through provoking the release of these signaling molecules.  
4.4.3 PKC and intracellular Ca2+ handling 
Of great importance, we elucidated the mechanism how the SP-activated PKC mediates 
the cardioprotection. By monitoring the resting Ca2+ level in single cardiomyocytes, we 
observed that SP lowered elevation of [Ca2+]i  during ischemia in a PKC-dependant 
manner. Such a timely rectification on elevated [Ca2+]i during ischemia challenge could 
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be therapeutically important, as uncontrolled elevation in [Ca2+]i could induce irreversible 
injuries like mitochondria dysfunction (Minezaki et al., 1994), membrane degradation 
and contractile derangement (Gross et al., 1999). If the ischemia is followed by 
reperfusion, the myocytes will exhibit hypercontracture at the onset of reperfusion due to 
massive stimulation on the contractile machinery by accumulated Ca2+ (Siegmund et al., 
1993). In perfused myocardium, this hypercontracture is manifested by contraction band 
necrosis (Ganote, 1983). Even if the necrotic myocardium can be replaced by scar tissues 
in a subsequent remodeling process, the akinetic fibrotic tissue will permanently impair 
the pumping function of the heart and when substantial enough will lead to heart failure 
(Richardson et al., 1996).  
To further corroborate the effect of H2S on resting Ca2+ during ischemia, we 
examined the myocyte hypercontracture at the onset of reperfusion. Indeed, SP reduced 
the development of myocyte hypercontracture through a PKC-dependent pathway. These 
beneficial effects triggered by SP and mediated by PKC could in turn at least partly 
account for the cardioprotection observed on cell viability, cell morphology, and cell 
function. It is also predictable that this limitation on development of Ca2+ overloading 
and hypercontracture in single cells would achieve further significant benefits by 
preserving contractile function in the intact heart.  
Previous studies have demonstrated an effective approach to attenuate myocyte 
hypercontracture by increasing SERCA activity (Abdallah et al., 2005). Since SR uptake 
through SERCA presents the dominant route for Ca2+ removal in cardiomyocytes, it is 
plausible that this reduced hypercontracture is due to a faster Ca2+ clearing from cytosol 
before reperfusion. Enlightened by this finding, we examined the SR- Ca2+ uptake rate as 
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well as the minor mechanism for Ca2+ removal, i.e. extrusion via NCX. We found that SP 
accelerated the clearing rate through both of these routes. Again, all these beneficial 
effects induced by SP were reversed by inhibition of PKC, implying that PKC may 
phosphorylate these calcium handling proteins and improve their function.  
In conclusion, the present study significantly advances our understanding on the SP-
induced cardioprotection by delineating the essential role of PKC in the context of 
signaling pathway. The results demonstrate that SP activates PKCα, ε and δ in 
cardiomyocytes, among which only activation of PKCε is secondary to the KATP channel 
opening. Such PKC activation accelerates cytosolic Ca2+ clearing and prevents 









Chapter 5 H2S preconditioning induces late cardioprotection in a rat 
model of myocardial infarction 
5.1 Introduction 
Myocardial infarction (MI) is the common presentation of ischemic heart disease. To test 
the cardioprotective effect of H2S in intact animals, we established a rat model of MI by 
occluding the left anterior descending coronary artery (LAD). To pave way for clinical 
studies, we investigated and fine-tuned the effect of H2S preconditioning and further 
made comparison between different administration regimes to investigate whether post-
MI treatment with H2S could produce comparable infarct-limiting effect and whether a 
combination of both could provide additional protection.  
5.2 Materials and Methods 
5.2.1 Animals 
The study protocol was approved by the Institutional Animal Care and Use Committees 
(IACUC) of National University of Singapore. Left ventricular (LV) MI was created in 7-
week-old male Sprague-Dawley rats. The rat was anesthetized by an intraperitoneal 
injection of ketamine (70mg/kg body weight) and xylazine (4.6mg/kg body weight). A 3-
cm catheter was inserted into the animal’s trachea and the animal was ventilated with a 
Havard respirator at 85 strokes per minute and tidal volume of 2.15 cc.  After 
thoracotomy at the fourth intercostal space, the heart was exteriorized and the left anterior 
descending coronary artery (LAD) was permanently ligated using 6-0 suture. The heart 




5.2.2 Experimental design  
The protocols were shown in Fig. 5-1. Rats in H2S preconditioning group received a 
single bolus of NaHS (a H2S donor) one day before surgery. NaHS was given 
intraperitoneally at doses of 0.1, 1, 3, 10, 30 µmol/kg body weight. Rats in H2S post-MI 
treatment group received an intraperitoneal bolus of NaHS immediately after surgery and 
once a day for two more days. NaHS was given at 0.1, 1, 10 µmol/kg body weight. Rats 
in the combo group were treated with a combination of preconditioning and post-MI 
treatment, that is, a bolus of NaHS one day before surgery plus one bolus a day for 3 days 
after surgery. Each group was compared with correspondent vehicle-treated MI, in which 
rats received surgery and saline injection in parallel with NaHS administration. For the 
time course study (Fig. 5-3A), rats received surgeries 1 day, 3 days or 5 days after NaHS 








5.2.3 Assessment of infarct size 
Infarct size and ischemic risk area were determined using Evans blue and 
triphenyltetrazolium chloride (TTC) staining. Three days after MI, animals were 
euthanized, the heart excised, and stained with 0.12% evans blue to define the area at risk 
(AAR; the nonperfused and hence unstained myocardium). The heart was then sliced into 
Figure 5-1. Experimental protocols. (A) H2S preconditioning group: rats received a single bolus of 
NaHS (a H2S donor) one day before surgery; (B) H2S post-treatment group: rats received an 
intraperitoneal bolus of NaHS immediately after surgery and once daily for two more days; (C) 
Combo treatment group: rats were treated with a combination of H2S preconditioning and post-MI 
treatment, namely, a bolus of NaHS given once daily from one day before till 3 days after surgery.  
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sections and incubated in 1% TTC in PBS for 15 minutes to define the area of infarction 
(INF; nonviable thus unstained myocardium). Infarct size, ventricle internal diameter and 
anterior wall thickness were assessed using computerized planimetry. 
5.2.4 Statistics 
All data are expressed as a mean ± SEM. Statistics were performed with one-way 
ANOVA followed by a Bonferroni post-hoc test. A P value less than 0.05 denotes a 
statistically significant difference.  
5.3 Results 
5.3.1 AAR/LV was consistent throughout the study 
Table 1 lists the number of animals in each group and the correspondent ratio of area at 
risk to total left ventricle area (AAR/LV).  No significant difference in AAR/LV was 
observed across groups.  
 
Table 1. List of experimental groups with their respective animal numbers and area at 
risk, expressed as the percentage of the left ventricle (AAR/LV). 
Study  Group N AAR/LV (%) 
MI-vehicle 7 52.6 ± 2.8 Preconditioning 
 NaHS Pre 0.1 7 50.6 ± 3.0 
 NaHS Pre 1 8 50.5 ± 4.5 
 NaHS Pre 3 7 52.9 ± 4.0 
 NaHS Pre 10 7 52.3 ± 1.7 
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 NaHS Pre 30 6 48.0 ± 2.9 
MI-vehicle 9 51.8 ± 3.3 Post-treatment 
 NaHS Post 0.1 7 49.6 ± 2.5 
 NaHS Post 1 7 50.2 ± 2.9 
 NaHS Post 10 8 50.8 ± 3.8 
MI-vehicle 8 50.4 ± 2.5 Combo treatment 
  NaHS Combo 0.1 7 51.2 ± 3.2 
 NaHS Combo 1 7 48.8 ± 3.6 
 NaHS Combo 10 10 52.4 ± 3.9 
MI-vehicle (1 day) 6 50.9 ± 2.5 Time course study 
 NaHS pre 1 (1 day) 6 49.4 ± 4.2 
 MI-vehicle (3 day) 7 53.4 ± 3.0 
 NaHS pre 1 (3 day) 6 50.7 ± 3.8 
 MI-vehicle (5 day) 6 51.3 ± 3.9 







5.3.2 H2S preconditioning reduced infarct size, LV dilatation and wall thinning in 
the heart undergoing MI  
A single bolus of NaHS was administered one day before MI (Fig. 5-1A). As shown in 
Fig. 5-2B, NaHS at 0.1, 1, 3, and 10µmol/kg significantly decreased infarct size per AAR 
as compared with MI-vehicle group. The optimal effect was found in rats receiving 1 
µmol/kg NaHS, which displayed a 78% reduction in infarct size. Representative mid-
ventricular cross sections of MI-vehicle and H2S preconditioning at 1 µmol/kg were 
shown in Fig. 5-2A. H2S preconditioning also remarkably reduced LV dilatation and wall 
thinning, as manifested by the decreased LV internal diameter (Fig. 5-2C) and increased 
anterior wall thickness (Fig. 5-2D) compared with MI-vehicle. Similar dose-response 
curves were observed, with significant effects found within a dose range of 0.1~3 















Figure 5-2. Effect of H2S preconditioning on infarct size and LV geometry. (A) Representative 
mid-myocardial sections of MI-vehicle and H2S preconditioning. (B-D) Dose-dependent effect of 
NaHS (0.1~30 µmol/kg) on infarct size (B), left ventricle internal diameter (C), and left ventricle 
anterior wall thickness (D). The data are presented as mean ± SEM. *, P<0.05, **, P<0.01, ***, 
P<0.001vs. MI-vehicle. N per group is shown in Table 1.  
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5.3.3 The protection of H2S preconditioning lasted at least 3 days after NaHS 
administration 
Rats preconditioned with NaHS (1 µmol/kg) were subjected to coronary occlusion on day 
1, day 3 or day 5 after NaHS administration (Fig. 5-3A). Strong infarct-limiting effects 
were observed on day 1 and day 3 (Fig. 5-3B), indicating that the protection lasted at 




Figure 5-3. Time course of the cardioprotection induced by H2S preconditioning. (A) Experimental 
protocol. (B) Infarct size in rats subjected to MI on day 1, day 3 and  day 5. The data are presented as 




5.3.4 The protection of H2S preconditioning could not be replaced with H2S post-MI 
treatment  
Based on the effective dose range of H2S preconditioning, we examined the effect of H2S 
post-treatment at 0.1, 1, and 10 µmol/kg NaHS given once daily for 3 days after the MI 
surgery (Fig. 5-1B). Rats receiving 1 and 10 µmol/kg NaHS also displayed a significant 
decrease in infarct size compared with correspondent MI-vehicle group (Fig. 5-4A). 
However, when compared with H2S preconditioning group at the same dose, the 
infarct/AAR was significantly lower in preconditioning groups than those in post-
treatment groups.  At the optimal dose of 1 µmol/kg NaHS for both groups, H2S 
preconditioning limited the infarct size to 13.1 ± 4.3% per AAR, representing a 78% 
reduction, while H2S post-treatment reduced the infarct size only by 38% to 37.5 ± 3.1% 
per AAR.  In addition, none of the doses in post-treatment group produced significant 
effect on LV dilatation and wall thinning, as indicated by LV internal diameter (Fig. 5-4B) 
and wall thickness (Fig. 5-4C). In contrast, H2S preconditioning significantly decreased 
LV internal diameter and increased wall thickness when compared with either MI-vehicle 
group or H2S post-treatment at 1 µmol/kg.   
We also tested whether a combination of H2S preconditioning and post-MI treatment 
could produce a synergic cardioprotection. Rats in the combo group received NaHS (0.1, 
1, or 10 µmol/kg) injection once daily from 1 day before till 3 days after MI surgery (Fig. 
5-1C).  As shown in Fig. 5-4A, a combo treatment of NaHS at all doses significantly 
decreased infarct size compared with correspondent MI-vehicle group. When comparing 
at the same dose collaterally, the infarct/AAR in combo group at 0.1 and 1 µmol/kg were 
significantly lower than that in post-treatment group but comparable to that in H2S 
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preconditioning group. Likewise, a similar trend was observed when assessing the LV 
parameters (Fig. 5-4 B&C). In addition, no significant difference in infarct size and LV 
geometry was observed across the three MI-vehicle groups injected with the three 
different administration regimes. These results indicate that the infarct-limiting effect of 
H2S preconditioning superseded that produced by post-treatment when both were 
administered. Continuous treatment after MI did not reinforce the effect of H2S 






Figure 5-4. Comparison on infarct size (A) and LV internal diameter (B) and LV anterior wall 
thickness (C) among H2S preconditioning, post-MI treatment and a combination of both (combo). 
NaHS was given at 0.1, 1, 10 µmol/kg for each group. The experimental protocol is shown in Figure 
1. The data are presented as mean ± SEM. *, P<0.05, **, P<0.01, ***, P<0.001 vs. correspondent 
MI-vehicle. N per group is shown in Table 1. 
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5.4 Discussion  
The present study demonstrated in an in vivo rat model that brief exposure to H2S 
restrains the extent of myocardial infarction that occurs in the next 72 hours through a 
PKC-dependent mechanism. Post-MI treatment with NaHS at the same doses for 3 days 
did not produce as pronounced infarct-limiting effect as observed in the preconditioning 
group. A combination of both did not produce additional benefit more than 
preconditioning alone. These results suggest that the effect of preconditioning is not 
replaceable with post-MI treatment even with multiple-administrations. The access to 
preconditioning, by and large, determines the outcome of the patients. Continuous 
treatment after MI is not necessary when the access to preconditioning has been secured. 
As always, studies in intact animals are of great importance to bridge the novel 
discoveries in basic research to clinical use. Since H2S has been proposed to be both 
cytoprotective (Kimura and Kimura, 2004; Whiteman et al., 2004; Whiteman et al, 2005) 
and cytotoxic (Deplancke and Gaskins, 2003; Yang et al., 2006), depending on the cell 
type and concentration used, fine-tuning the NaHS dose is particularly crucial in in vivo 
experiments. Inappropriate selection of dose range may lead to misappraisal of its 
therapeutic value or even to contradictory results. The prevailing dose of sulfide donor 
used in the most of recent cardiovascular studies is above 10 µmol/kg body weight per 
day (Cai et al., 2007; Meng et al., 2007; Sivarajah et al., 2007; Zhu et al., 2007). However, 
we demonstrated in a preconditioning model that a single bolus of NaHS at 0.1~1µmol 
/kg was sufficient to afford marked protection against MI. Increasing the dose from 
1µmol /kg only decreased the protection.  
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We also performed a time course study to determine the duration of the protection. 
Sivarajah and colleagues (Sivarajah et al., 2007) showed that NaHS pretreatment, 15 min 
before MI, produced immediate protection, while we found that H2S preconditioning 
produced late protection which lasted at least 3 days.  The vastly different duration of 
protection supports the concept that the late phase of preconditioning may have greater 
clinical usefulness (Bolli, 2000). It also merits further study to investigate whether 
continuous administration of NaHS at 48-72h intervals will extend the protection 
duration and whether repeated administration will result in the maintenance of a 
defensive phenotype.  
Although preconditioning is inferior to treatment in terms of practical convenience, 
the ultimate goal should be identification and implement of the most effective approach 
to intervene with MI. Elrod and colleagues recently reported that H2S donor administered 
at the time of reperfusion significantly decreased infarct size (Elrod et al., 2007). 
However, no comparison has so far been conducted between the effectiveness of H2S 
preconditioning and post-MI treatment. Our current study evidenced that H2S 
preconditioning produced far stronger infarct-limiting effects than H2S post-treatment in 
this model, indicating that the effect of preconditioning with a single bolus of NaHS 
could not be replaced with multiple post-MI administration of the sulfide donor. This 
result bears great clinical implication for those potential patients at high risk of 
myocardial infarction. Brief exposure to low dose of H2S may make them survive a MI 
which would otherwise be a lethal attack. However, much less benefit could be provided 
by H2S treatment after the attack has occurred. To substantiate above finding, we treated 
the rats with a combination of both preconditioning and post-MI treatment. The 
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combined treatment produced an infarct-sparing effect comparable to that produced by 
H2S preconditioning alone, which further underscores the importance of access to NaHS 
before the attack.  
In the current study, we also examined the effect of H2S on LV chamber dilatation 
and wall thinning by assessing the LV internal diameter and anterior wall thickness. 
Changes in these parameters almost followed the same trend as infarct size. It is worthy 
of note that H2S post-treatment did not reduce LV dilatation and wall thinning to a 
statistically significant extent in spite of deceasing infarct size, while preconditioning was 
able to effectively limit infarction,  chamber dilatation and ventricle wall thinning at the 
same time. These effects of H2S preconditioning on ventricular geometry hint a better 
preserved LV pump function and a reduced chance of post-MI ventricular rupture.  
With accumulating data supporting its protective effect, H2S possesses the potential to 
be developed into an inhaled gas or a parenteral injectable, which could actualize the 
power of ischemic preconditioning without feasibility problem. Importantly, the dose of 
H2S we identified most effective in the preconditioning model is over 250 folds lower 
than its LD50 value (Warenycia et al., 1989). Therefore, for the high-risk population, brief 
exposure to H2S every 3 days represents a cost-effective prevention measure.    
In conclusion, the current study provides the first evidence that 1) preconditioning 
with low concentration of H2S produces delayed cardioprotection against myocardial 
infarction and 2) H2S preconditioning was far more effective than post-treatment in 




Chapter 6 General discussion 
The whole investigation profiled the role of hydrogen sulfide in the cardioprotection 
against ischemia and reperfusion insult, focusing on its potential as a preconditioning 
agent. The evidence from both in vitro and in vivo studies consistently pointing towards 
that H2S preconditioning produces potent cardioprotective effects, which translated into 
decreased cell death, prevention of intracellular calcium overload, preserved contractile 
function and restraint of infarct size. The dose-response curve, both in isolated 
cardiomyocytes and in intact animal, is bell-shaped: raising the dose of sulfide above the 
optimal dose results in diminished therapeutic efficacy. 
Using cardiomyocytes, we also identified several essential signaling components and 
intracellular events underlying the protection afforded by H2S preconditioning. Fig. 6-1 
summarizes the current understanding of H2S preconditioning by proposing a signaling 
pathway: with free passage through the plasma membrane, H2S directly opens 
sarcolemmal KATP channel which activates PKCε. Or through some unknown 
mechanisms, H2S could also directly or indirectly stimulate PKCα and PKCδ. Activated 
PKC isoforms then translocate from cytosol to membrane fraction of the cell, where 
calcium handling proteins such as SERCA and NCX are located. PKC may enhance the 
function of these proteins whereby the cytosolic calcium clearing is accelerated. During 
ischemia and reperfusion, fast calcium clearing results in attenuated calcium 
accumulation in the cytosol and reduced hypercontracture of the myocytes, both of which 
contribute to the decrease in infarct size and preservation of contractile function.  
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However, we also bear in mind that the whole scenario of the signal transduction 
could be much more complicated. The signaling pathway outlined above is by no means 
the only goings-on after H2S preconditioning. Taking PKC as a nodal point, a spectrum 
of endogenous molecules, like NO, adenosine, and free radicals, could be its upstream 
triggers, while its downstream targets could range from mitogen-activated protein kinases, 
heat shock proteins to mitochondria proteins (Sanada and Kitakaze, 2004). It is more 
likely to be a signal network than single pathway which transforms the extracellular 






Figure 6-1. The proposed signaling pathway for SP-induced cardioprotection (the yellow route). H2S 
activates different PKC isoforms directly (dashed line) or indirectly though the opening of KATP or 
other unknown mechanisms (dashed line). The activated PKC isoforms stimulate the Ca2+ handling 
proteins (i.e. NCX and SERCA) and thereby facilitate the clearing of cytosolic Ca2+. During ischemia, 




In the present study, we observed three PKC isoforms activated by H2S 
preconditioning, but the inhibitor chelerythrine could not distinguish the one or ones that 
is necessary for the genesis of the late cardioprotection. It is likely that different isoforms 
act on different substrates at various subcellular sites and afford the protection from 
diverse aspects (Mackay and Mochly-Rosen, 1999). Assigning specific roles to each PKC 
isoform may depend on the availability of isoform-specific antagonists, siRNA or PKC-
isoform knockout animals. 
Using intact animal model, we also demonstrated that H2S preconditioning could 
provide much stronger protection than H2S post-treatment. This finding prompts us to 
reason that the mechanisms underlying preconditioning and post-treatment are different. 
H2S preconditioning is more likely to protect by switching the heart to a defensive state 
against ischemia insult. The opening of KATP channels, activation of PKC isoforms as 
well as altered intracellular calcium handling are accomplished prior to the attack. Thus 
even though exogenous H2S was not present at the time of attack, the protection was still 
well executed. In contrast, without H2S preconditioning, the endogenous defensive 
system could be overwhelmed by the injuries caused by lethal ischemia, and supplement 
with exogenous H2S after the attack could only provide limited benefit. The effect of H2S 
-posttreatment may only rely on the ability of sulfide to reduce inflammatory responses 
(Zanardo et al., 2006) and to neutralize cyotoxic reactive species such as peroxynitrite 
(Whiteman et al., 2004), which may relieve the oxidative stress to some extent but not 
likely to reverse infract myocardiums back to normal.  
Another important question is that the local H2S concentration achieved using sulfide 
donor is unknown. The basal H2S level in the rat serum was reported to be ~46µM and 
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physiological range was assumed to be within 50~150 µM, depending on the tissue of 
interest (Wang, 2002). However, in our in vivo study, the dose of H2S that produced 
maximum protection was at 1µmol/kg, which may increase the circulating H2S by 
10~20µM (the blood volume of a 250g rat is ~15.5ml) (Lee and Blaufox, 1985). If there 
is a substantial background level of sulfide, how is it possible that relatively small 
increment can produce so significant biological effects? One possibility is that the 
biological sulfide-eliminating systems might get saturated by sudden exposure to sulfide, 
and the non-metabolized sulfide locally in the heart triggers the downstream biological 
effects. 
However, evidence is accumulating in favor of another possibility—the exact free 
sulfide baseline levels in blood and tissues are probably lower than the reported levels. 
Although we do not question the detection of endogenous H2S, we must note that the 
reported baseline concentration of H2S is high enough to emit the characteristic 
unpleasant H2S smell, whereas the blood samples actually do not. In two recent reviews 
by Li (Li and Moore, 2008) and Szabó (Szabó, 2007), both authors mentioned that the 
colorimetric assays or ion selective electrode assays used to measure H2S concentrations 
in most studies are likely to liberate sulfide from its bound forms, thereby generating 
concentrations that are likely to represent a mixture of free and bound sulfide (Hannestad 
et al., 1989; Togawa et al., 1992; Ogasawara et al., 1993). Using a lately-developed 
polarographic H2S sensor, Whitfield and colleagues have recently reappraised sulfide 
concentration in vertebrate blood (Whitfield et al., 2008). They found that H2S gas was 
undetectable (<100nM) in blood from numerous animals, including lamprey, trout, 
mouse, rat, pig and cow. Interestingly, exogenous H2S was also rapidly removed from 
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blood or plasma. Indeed, as a highly reactive molecule, H2S could either be broken down 
rapidly by enzymes, sequestered by binding to haemoglobin, or react chemically with a 
number of species abundant in tissues, including superoxide radical, hydrogen peroxide, 
peroxynitrite and/or hypochlorite (Li and Moore, 2008). The key issue that needs to be 
addressed in future studies is how the fleeting presence of free sulfide achieved 
subsequent lasting biological effects.  
To date, simple sulfide salts, most commonly NaHS, have been the H2S-releasing 
drugs used in most biological experiments, including our present study. NaHS is known 
to release H2S instantaneously in aqueous solution. Because the release of endogenous 
H2S from cells is likely to occur in lesser amounts and at a much slower rate, NaHS may 
not mimic the biological effects of naturally produced H2S. However, based on findings 
in the current study, NaHS is able to produce both immediate and delayed protection 
against cardiac ischemia, even if it only transiently increases the circulating H2S levels. 
Thus for the preconditioning purpose, NaHS qualifies as an economical option. 
Development of organic compounds that slowly release free H2S over extended periods 
of time could be more useful for treating patients who fail to access to H2S 
preconditioning before myocardial infarction occurs or treating other diseases where long 
period of H2S treatment has shown therapeutic effects.   
Another potential area is the development of H2S as an inhaled gas or as a parenteral 
injectable. Inhaled NO has set a precedent for development of medical gases. NO was 
also first known as a toxic gas and is currently approved for use in infants with primary 
pulmonary hypertension (Kinsella and Abman, 2005; Hillier, 2003). However, the 
unpleasant odor of H2S may pose more problems for administration, which could 
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necessitate the implementation of appropriate trapping systems to prevent from spreading 
into environment and exposure of medical personnel (Szabó, 2007). With enteral or 
parenteral formulations, odor would not create a problem, but manufacturing and 
formulation issues remains challenging compared with conventional chemical compound. 
In addition, animal safety data are still lacking with respect to parenteral or enteral 
administration of H2S. Although sulfide is an endogenous substance, all exogenous 
sulfide delivery systems would be required to pass stringent safety and efficacy tests in 













Chapter 7 Conclusion 
The current study demonstrated that H2S is both necessary and sufficient for the 
development of early and late phases of cardioprotection against ischemia. Cells or 
animals preconditioned with H2S displays a phenotype tolerant to experimental ischemia 
or myocardial infarction, manifested by the decreased cell death or infarct size. Such 
protection is mediated by sarcolemmal KATP channels, NO and PKC. Activation of PKC 
results in accelerated cytosolic Ca2+ clearing, which prevents development of Ca2+ 
overloading and myocyte hypercontracture during ischemia/reperfusion insult. These 
findings demonstrate the potential of H2S preconditioning as an effective intervention 
approach against ischemic heart disease. For the high-risk population, H2S 
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